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CHAPTER 1
STATEMENT OF THE PROBLEM
Heart failure is a progressive disease that poses a massive burden on human life
both in terms of mortality and monetarily. In 2019 cardiovascular disease was attributed
to 18.6 million deaths world-wide, and in the United States the cost of treatment is
estimated to total more than $360 billion annually1. While patient management has
increased tremendously, the only “cure” for heart failure remains to be a heart
transplant. More recent therapeutics aim to improve cardiovascular function by targeting
the contractile mechanisms of cardiomyocytes, the contractile cells of the heart.
However, the beneficial effect of these treatments have had varying effectiveness in
clinical trials2, revealing that this field of therapeutics has room for growth and
development.
Cardiomyocyte contraction involves a complex interplay between calcium
handling proteins (associated with the plasma membrane and sarcoplasmic reticulum)
and the filamentous proteins (termed myofilament proteins) which physically contract
along one another. Modifications to both calcium handling and myofilament proteins can
alter their contributions to contractility. A common, and reversible, type of modification
that affects myofilament function is phosphorylation. Phospho-groups are added by
enzymes called kinases, and oftentimes a single kinase will have the ability to target
multiple substrates. Kinases can become dysregulated in heart failure,3 causing a
1

plethora of detrimental downstream

effects4.
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For this reason, kinases have attempted to

be targeted therapeutically in disease. Unfortunately, inhibition of kinases can result in
off-target effects, because only a subset of their downstream effectors are detrimental.
However, kinases have endogenous mechanisms of maintaining their own substrate
specificity, such as changes in subcellular localization or kinase activity. Therefore a
more appropriate therapeutic strategy may be to target these mechanisms themselves
in order to manipulate downstream signaling pathways that occur in disease.
Glycogen Synthase Kinase 3β (GSK-3β) is a prolific Serine/Threonine kinase5. It
has been heavily studied in the heart due to its role in signaling pathways that contribute
to hypertrophy, proliferation, and autophagy6-8, all of which can become impaired in
heart failure, making it an attractive therapeutic candidate. However, different models of
GSK-3β manipulation have been contradictory or inconclusive with one another in terms
of whether GSK-3β activity is beneficial or harmful in heart disease9-13. One reason for
this may be that GSK-3β has several different subcellular pools within the
cardiomyocyte (cytosol, nucleus, mitochondria, etc.), and targeting all of these pools, as
opposed to just those associated with depressed cardiomyocyte function, leads to off
target effects, or negates any effect.
GSK-3β has more recently been identified as interacting with the myofilament.
GSK-3β activity was found to be downregulated in a dog model of heart failure, and,
importantly, this activity was uncoupled from its cytosolic signaling pathways14. The
decrease in GSK-3β correlated with worsened myofilament function, which could be
rescued by in vitro treatment with recombinant GSK-3β. This work proposed that a
separate subcellular population of GSK-3β could phosphorylate the myofilament and

3

modulate function. However, this model system was not able to adequately confirm this,

as the GSK-3β treatment experiments were performed in vitro and it was unknown if this
same mechanism could occur physiologically. Additionally, as these experiments were
performed in a complicated disease model- identifying worsened function as a direct
effect of GSK-3β was impossible. Therefore, the central hypothesis of this dissertation is
that GSK-3β localizes to the myofilament and modulates myofilament function in vivo
and that this localization is relevant in heart failure. The goal of this dissertation is to
determine if the previous in vitro work finding that GSK-3β can modulate myofilament
function holds in an in vivo model, and to elucidate the mechanism by which GSK-3β
localizes to the myofilament and affects function. This hypothesis was tested via the
following three aims:
Aim 1: Characterize GSK-3β’s Myofilament Localization and Phosphorylation
Targets
GSK-3β is a double-edged sword as a therapeutic target. Its attractiveness lies in
the fact that it regulates pathways that become dysregulated in disease. However,
because it is so promiscuous, with over 500 proposed targets, manipulation of this
kinase leads to off-target effects. Therefore, the ability to alter a singular function of
GSK-3β is extremely attractive. Recently it has been found that GSK-3β can
phosphorylate myofilament targets, revealing a new potential subcellular pool14. My
working hypothesis is that GSK-3β localizes to the myofilament and phosphorylates
myofilament substrates in vivo. GSK-3β myofilament localization was explored by
probing for GSK-3β in myofilament enriched fractions of the left ventricle and
immunofluorescence. Mechanisms of this localization were investigated by

overexpressing GSK-3β phospho-mutants in neonatal rat ventricular cardiomyocytes
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and quantifying GSK-3β’s myofilament interaction. To determine in vivo phosphorylation
targets of GSK-3β, myofilament fractions from an inducible, cardiomyocyte specific
GSK-3β KO mouse was utilized for phospho-proteomics.
Aim 2: Determine if GSK-3β Can Modulate Myofilament Function in Vivo and
Explore Mechanism(s) by Which this Occurs
Previous work in a dog model of heart failure has shown that treatment of
skinned myocytes with recombinant GSK-3β increases calcium sensitivity, a contributor
to myofilament contractility14. However it was unclear if GSK-3β can modulate calcium
sensitivity in vivo. In addition, as this work was performed in a disease model, it is
difficult to determine which changes in myofilament function are due to the disease as
opposed to a direct effect of GSK-3β. My working hypothesis is that GSK-3β modulates
calcium sensitivity of the myofilament in vivo. To determine the in vivo role of GSK-3β
on myofilament function, skinned myocytes from inducible, cardiomyocyte specific GSK3β KO mice were used for functional experiments in which calcium sensitivity and
maximal force production were measured. Tissue from these animals was then used to
explore mechanisms of calcium sensitivity modulation, such as phosphorylation of thin
filament proteins, changes to lattice spacing, and alterations to titin-based passive
tension. Finally, the role of one of GSK-3β’s myofilament targets, identified in Aim 1,
actin binding LIM domain protein-1 (abLIM-1), was explored in the context of
myofilament function.

Aim 3: Explore Myofilament GSK-3β Localization in Heart Failure and Determine
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Its Functional Relevance
“Heart Failure” is a blanket term for a larger and heterologous group of diseases.
For that reason, it is even more important to develop precision medicine to target the
specific contractile deficiency, which can vary depending on disease etiology. The
literature shows that GSK-3β localization and activity can be disrupted in animal models
of heart failure, however it is unknown if these same findings are true in human heart
failure. My working hypothesis is that myofilament GSK-3β localization become
dysregulated in heart failure. This was tested by utilizing a large bank of left ventricular
tissue from patients who did not have heart failure (Non-failing) and those from end
stage heart failure (HF) patients with dilated (DCM) or ischemic (ICM) cardiomyopathy.
The tissue was fractionated and GSK-3β was probed for in myofilament and cytosolic
fractions. A subset of these samples were also used for force-calcium measurements to
determine if changes in myofilament GSK-3β correlates with depressed myofilament
function. To explore the effect of heart injury on GSK-3β localization in an earlier stage
of heart failure, a mouse injury model (myocardial infarction) was used and GSK-3β
myofilament localization was quantified 48 hours after injury.
These studies investigate, for the first time, in vivo localization of GSK-3β to the
myofilament, phosphorylation of myofilament specific substrates, and its effect on
myofilament function. In addition, this work identifies a novel mechanism by which GSK3β modulates length-dependent activation. Furthermore, the investigation of altered
myofilament GSK-3β in both human and mouse heart failure, in conjunction with GSK-

3β’s functional impact at the myofilament, highlights a potential mechanism to be
harnessed therapeutically to improve cardiomyocyte function.
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CHAPTER 2
LITERATURE REVIEW
Heart Failure
Heart failure is a progressive condition which occurs when the heart is unable to
pump enough blood to meet the demands of the body. Managing heart failure is
complicated, because it is not a homogenous disease. In fact, “heart failure” is a blanket
term that covers a collection of phenotypes and is typically preceded by
cardiomyopathy, an acquired or inherited disease of the myocardium (heart muscle) that
reduces its pumping ability. Broadly, cardiomyopathy can be divided into two main
groups: ischemic and non-ischemic cardiomyopathy15, 16. Ischemic cardiomyopathy
typically stems from coronary artery disease, which can lead to myocardial infarction17.
These hearts are characterized by areas of infarcted tissue in which cardiomyocytes are
replaced by a non-contractile fibrotic scar. Due to weakened systolic function, these
hearts can become dilated, with enlarged ventricular chambers and thinned walls. Some
patients also develop arrythmias if the conduction system has been damaged18. Nonischemic cardiomyopathy can present with a very diverse range of phenotypes. Genetic
mutations can lead to dilated cardiomyopathy (DCM)19 as well as hypertrophic
cardiomyopathy (HCM)2, 20. HCM is characterized by thickened, hyper-contractile
ventricular walls and impaired relaxation during diastole. Other mutations, such as those
that occur in ion channels, can also lead to arrythmias which impair cardiovascular
7

function21.

Aside from genetic causes, non-ischemic cardiomyopathies can also stem

from comorbidities such as diabetes22 and toxicity from cancer treatments16, 23.
Historically, heart failure has been associated with a low ejection fraction (EF).
EF is calculated from echocardiography measurements and is the percentage of blood
ejected from the left ventricle during each contraction. Over the course of the past
twenty years, it has become apparent that patients can develop the symptoms of heart
failure, stemming from increased diastolic filling pressure, while still maintaining what is
considered to be a normal ejection fraction24. This type of heart failure is referred to as
heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure, and
many therapeutics that are successful in managing heart failure with reduced ejection
fraction (HFrEF) are ineffective in HFpEF25.
The success of therapeutics is dependent upon the disease phenotype.
Traditional therapeutics include targeting the renin-angiotensin system to prevent
chronic vasoconstriction, which can lead to cardiomyocyte hypertrophy, fibrosis, and
sodium and fluid retention26. Another class of pharmaceuticals which are used to treat
heart failure symptoms are beta-blockers, which are prescribed to slow heart rate and
prevent the heart from over-working itself27. However, because beta-blockers also
decrease the strength of contraction in addition to effecting heart rate, there are
situations in which they are not beneficial, specifically in patients with low blood
pressure. Patients are also prescribed therapeutics which strengthen contraction.
Digoxin is glycoside which promotes increased strength of contraction via targeting
sodium-calcium exchange, which increases intracellular calcium28, 29. However, its use
must be closely monitored as this increase in calcium can also cause arrythmias and
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hyperkalemia29.

Recently, sodium glucose co-transporter 2 (SGLT2) inhibitors, which

9

inhibit glucose reabsorption by the kidney, have been shown to be beneficial in
improving morbidity and mortality in heart failure patients. Originally developed for
treating patients with type 2 diabetes and heart failure, SGLT2 inhibitors are beneficial
in lowering blood pressure, diuresis, and cardiac energy metabolism.
The above therapeutics are typically prescribed in combination with one another to
lower blood pressure, prevent water retention, and improve the strength of contractility.
However, this approach is only beneficial in systolic heart failure. Unfortunately, there
are currently no therapeutics that have been shown to be beneficial in diastolic heart
failure, such as HCM, however, there are currently pharmaceuticals in development
(see below) which aim to improve function in this group of patients.
With a limited number of therapeutics and diverse presentations of heart failure, it
is unsurprising that only one third of patients successfully respond to medication30.
Technological advances in genomic sequencing and molecular characterization now
point to precision-based approaches in treating heart failure patients30, 31. A promising
group of therapeutics aims to target cardiac dysfunction from a cellular perspective.
Weakening of the heart stems from dysfunction of the contractile cells, called
cardiomyocytes, and there has been a more recent push to develop pharmaceuticals
that improve function by targeting contractile mechanisms of the cardiomyocytes. A
small number of these drugs have entered clinical trials and have shown mixed results
in improving function and short-term mortality2.

The Sarcomere

10

The myocardium of the heart is composed of the following main cell types:
cardiomyocytes, cardiac fibroblasts, smooth muscle cells, endothelial cells, and immune
cells. Each cardiomyocyte contains repeating units called sarcomeres composed of a
lattice of thick filaments (primarily myosin) and thin filaments (primarily actin,
tropomyosin, and troponin), as well as an elastic filament, titin32 (Figure 1). During
contraction myosin binds to actin and pulls on the thin filament, shortening the
sarcomere and generating force. Titin and the thin filament anchor to structures called
z-discs, which delineate the ends of the sarcomere. In addition to anchoring filaments,
z-discs are also integral for transmitting the force of contraction across sarcomeres33.

Figure 1. The Main Components of a Sarcomere. 1. Z-discs (green) 2. Thin filaments
(blue), 3. Thick filament (red), and 4. Titin (dark blue)
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Contraction: An Overview
Action potentials are initiated in the sinoatrial node by specialized pacemaker
cells34. The action potential passes through a conduction system and across adjacent
cardiomyocytes via gap junctions. Within an individual cardiomyocyte, the signal passes
along transverse, or t-tubules, which are invaginations of the sarcolemma, or cell
membrane, of cardiomyocytes. T-tubules contain microdomains of ion channels,
specifically voltage-gated L-type calcium channels (LTCC), and align these channels in
close proximity to calcium channels like the ryanodine receptor (RYR) in the
sarcoplasmic reticulum (SR)35. At rest, or diastole, cytosolic calcium concentrations are
very low, (~100 nM), because calcium is sequestered, primarily, in the SR. Excitation
via the action potential opens the LTCC on the sarcolemma, causing an influx of
calcium into the cytosol36, 37. This influx of calcium activates RyR on the SR, causing
cytosolic calcium concentrations to increase up to 1 µM 38, 39 in a process termed
calcium induced calcium release (CICR). This influx of calcium initiates contraction of
the sarcomere40, referred to as excitation-contraction coupling.
When cytosolic calcium concentrations increase, contraction is first initiated at
the thin filament. There, calcium binding to Troponin C (TnC), which a member of the
troponin complex. Troponin is composed of a complex of three proteins: TnC, Troponin
I (TnI), and Troponin T (TnT), and each play an important role in thin filament
activation41, 42. At diastolic levels of calcium, another thin filament protein, tropomyosin,
sterically hinders the ability of myosin to bind to actin. Binding of calcium to TnC induces

a conformational change in

TnC43,
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and thus, TnI. This shift relieves the inhibition of TnI

on tropomyosin, which then shifts away from the myosin binding sites on actin. The
process of thin filament activation occurs in three states: Blocked (tropomyosin fully
covering the myosin binding sites), Closed (tropomyosin beings to shift), and Open
(tropomyosin is fully moved away from the myosin binding sites)44.
The process by which myosin interacts with actin to cause cross-bridge cycling
involves several steps. Myosin binds ATP, and this ATP is hydrolyzed by the ATPase
domain of myosin. This puts the myosin head into a high-energy state. Myosin, now
bound to ADP and Pi binds actin. Binding to actin causes the release of ADP and Pi,
and this energy release causes myosin to pull on actin, referred to as the power stroke.
Myosin then binds to ATP again, which causes a conformational shift and detachment
from actin.
Recently, myosin modulators have been developed which target contractility
without modulating calcium handling, avoiding pro-arrhythmic effects45. These
modulators can be further classified as myosin activators or inhibitors. In heart failure
that is hyper-contractile, such as HCM, pharmaceuticals that target decreased
contractility and increased relaxation are beneficial. MYK-461 (Mavacamten)46 is a small
molecular allosteric inhibitor of myosin, which stabilize the auto-inhibited, super relaxed
state of myosin47, 48. In the super-relaxed state, myosin heads fold back along the S2
myosin backbone, which results in very slow ATPase activity and decreased force
production49. Mavacamten has undergone both phase II and phase III trials50-52, which
had promising results in improving LV outflow tract gradients in patients with obstructive
HCM, however it was not effective in non-obstructive HCM patients53.

Alternative to myosin inhibitors, myosin activators aim to increase force
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production, with the goal being to improve contractile function is patients suffering from
systolic heart failure. Omecamtiv Mecarbil (OM) was initially identified as a myosin
activator54, however further work showed that OM actually binds and inhibits myosin55. It
has been proposed that the binding of OM to myosin stabilizes the open state of the thin
filament, allowing non-OM bound myosin to attach55. While Phase II trials of OM were
promising, Phase III trials resulted in a modest effect size, with the primary endpoint
being met in only 37% of the OM group. A second phase III trial is currently
underway.56, 57
Calcium Sensitivity
Contractility is dependent upon the response of the myofilament to calcium. The
relationship between the concentration of free calcium ions available for binding to TnC
and the amount of force generated by muscle is termed “myofilament calcium
sensitivity”58. Properties of striated muscle that contribute to calcium sensitivity include
the on and off rates of calcium binding to TnC, thin filament inhibition of myosin binding
sites, and myosin-actin cross-bridge properties59. While the term “calcium sensitivity” is
a simplification of a complex process and should not be used as a sole indicator of
muscle function58, experimental measurements of calcium sensitivity can provide
important insights into the mechanical capabilities of the sarcomere. Myofilament
calcium sensitivity has been found to be altered in human heart failure and is associated
with several mutations in thin filament proteins60-63. Experimentally, calcium sensitivity is
calculated from fitting force measurements taken at different calcium concentrations to a

Hill equation from which an EC50 can be generated. Rightward and leftward shifts in
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these curves represent changes in calcium sensitivity (Figure 2).

Figure 2. Steady-state Force-calcium Curve Shifts. Sigmoidal curves are generated
by fitting force measurements at different calcium concentrations to a Hill equation. A
rightward shift of the curve) represents a decrease in calcium sensitivity. A leftward shift
of the curve an increase in calcium sensitivity.
Several proteins have been identified as modulators of calcium sensitivity and have
been summarized in Table 1.
Troponin I
Multiple modifications to TnI have been connected to changes in myofilament
calcium sensitivity. TnI is the target of multiple kinases via opposing signaling pathways,
which would allow its effect on calcium sensitivity to be quickly altered based on
demand. The most well described TnI sites are S23/S24, known targets of protein
kinase A (PKA) during beta-adrenergic signaling, which results in decreased calcium
sensitivity and accelerated relaxation64-66. When TnI is phosphorylated at these
residues, the interaction between TnC and TnI, required for thin filament activation, is

weakened67, 68.

Chronic stimulation and desensitization of beta receptors cause
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pS23/S24 to become depressed in heart failure, which contributes to
hypersensitization69.
There are additional sites on TnI that contribute to calcium sensitivity that have
less elucidated mechanisms. Several residues (S43/S45, and T144) are targets of
protein kinase C (PKC)70-73. Interestingly, these sites have opposing effects on calcium
sensitivity, with pS43/S45 causing desensitization and pT144 resulting in sensitization.
Both sites have been found to be increased in heart failure. Additionally, TnI is
phosphorylated at S149/S150 by 5’ adenosine monophosphate-activated protein kinase
(AMPK) and serine/threonine protein kinase (PAK1), which increases calcium
sensitivity74, 75. The net effect of TnI phosphorylation on calcium sensitivity is likely an
interplay of multiple phosphorylation sites76.
Troponin T
TnT anchors TnC and TnI to tropomyosin and is believed to be important for
transmitting shifts in the troponin complex to tropomyosin upon calcium binding. Like
TnI, it is also a target of PKC, and phosphorylation at T206 leads to a decrease in
calcium sensitivity. The mechanism by which this occurs is believed to be through the
blunting of this signal transmission from troponin to tropomyosin. TnT has also been
shown to be phosphorylated at S278/T287 by Rho associated protein kinase III
(ROCKIII), a kinase that can become upregulation in heart failure, specifically during
hypertrophic signaling. Targeting of TnT by ROCKIII causes an increase in calcium
sensitivity 77, 78.

Cardiac Myosin Binding Protein-C
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Cardiac Myosin Binding Protein-C (cMyBP-C) is a large (140kDa) protein that
has domains capable of interacting with both the thick and thin filaments79. While its C
terminus contains domains which bind to the myosin backbone, its N-terminus,
specifically the C0-C2 domains, can interact with both the myosin head, actin, and
tropomyosin. Myocytes from cMyBP-C KO mice and mice lacking the C0-C1 domains of
cMyBP-C have decreased calcium sensitivity and develop heart failure at an early
age80, 81. PKA targets three residues (S273/S282/S302) on cMyBP-C located in the Mdomain, which interacts with the myosin head, and these sites increase calcium
sensitivity independently of PKA’s TnI targets during beta adrenergic stimulation.
cMyBP-C has been shown to inhibit cross-bridge cycling, acting as a brake on myosin.
Phosphorylation on these residues is believed to increase calcium sensitivity by
relieving this inhibition82.
Myosin Light Chain
Myosin Light Chain 2 (MLC2) is part of the complex making up the myosin head.
Phosphorylation at S15/S19 by myosin light chain kinase (MLCK) increases calcium
sensitivity83, 84 through increasing the rate of force redevelopment (Ktr)85. S1/S19 have
been found to be decreased in end stage heart failure.
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Table 1. Proteins and Phosphorylation Sites Which Contribute to Calcium
Sensitivity. Troponin I = TnI, Troponin T = TnT, Myosin Light Chain 2= MLC2,
Cardiac myosin binding protein C = cMyBP-C, Protein Kinase A = PKA, Protein
Kinase C= PKC, 5’ adenosine monophosphate-activated protein kinase = AMPK,
Serine/threonine-protein kinase PAK 1 = PAK1, Rho associated protein kinase III =
ROCKIII, Myosin light chain kinase = MLCK; Adapted from Kirk et al., 2014

Location

Protein

Site

Kinase

Effect on
Ca2+
Sensitivity

Thin
Filament

TnI

S22/S23

PKA

Decrease

Pi et al, 2003

S43/S45

PKC

Decrease

Burkart et al, 2003;
Kirk et al, 2009

T144

PKC

Increase

Wang et al, 2006;
Kirk et al, 2009

S149/S150

AMPK, PAK1

Increase

Buscemi et al, 2002;
Nixon et al 2012

T206

PKC

Decrease

Sumandea et al
2003

S278/T287

ROCKIII

Increase

Vahebi et al, 2005

MLC2

S15/S19

MLCK

Increase

Van der Velden et
al; 2003

cMyBP-C

S273/S282/S
302

PKA

Increase

Chen et al, 2010;
Sadayappan et al,
2011

TnT

Thick
Filament

Reference

Titin and Its Contribution to Myofilament Function
Titin is the largest protein at ~4,200 kDa, stretching an entire half-sarcomere
length from the Z-disc (where it anchors via T-cap) to the M-band (where it anchors to
myosin via myomesin)86. In mice, titin knock-out produces a drastic phenotype: animals

develop DCM which results in premature death. This is attributed to sarcomere
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disassembly that impedes normal myofilament function87. Titin mutations, specifically
truncation mutations, have been found in high prevalence in patients with DCM88.
Studies expressing these mutations in induced pluripotent stem cell derived
cardiomyocytes (iPSC-CM) found that sarcomeric organization and force production
were impaired89. Titin’s large size and overlap with the other filaments may allow it to
act as a scaffold and blueprint for sarcomergenesis90.
Functionally, titin maintains the passive tension of the cell through its elastic iG
repeats, PEVK, and N2B domains near its N-terminus. Sarcomeres undergo a range of
stretch and slack during both active contraction and passive stretch. As sarcomere
length increases, the elastic domains of titin extend, generating tension.
The functional impact of titin is dependent on the expression of its splice variants.
The I band region of titin can become heavily spliced by RNA binding motif protein 20
(RBM20) to produce two primary isoforms (N2B and N2BA)91. The shorter, stiffer N2B
isoform becomes the predominant isoform after development. However, overexpression
of N2B can lead to increased passive tension that results in pathological stiffening and
impaired relaxation, like is seen in hypertrophic cardiomyopathy92. Alternatively,
increased expression of N2BA results in a more compliant titin and is associated with a
dilated ventricle. It should be noted that there are additional, smaller, more recently
identified titin isoforms called Chronos and Novex3 that likely also contribute to titin’s
myofilament function93, 94.
Titin isoform switching in disease is the result of chronic stress on the heart and
is thought to be compensatory. This occurs gradually, as it requires changes in

transcription and protein translation. Titin’s passive tension can also be affected more
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acutely by phosphorylation. Targeting of the proximal Ig domains by PKA results in
decreased passive tension95, while targeting of the PEVK domain by
calcium/calmodulin-dependent protein kinase (CAMK) results in increased passive
tension96. More recent work has also shown that other modifications such as acetylation
change the charge state of amino acids and affect the ability of the coiled elastic
domains to stretch97.
In addition to passive stretch, titin has more recently been found to be a
contributing factor to active tension as well, specifically during stretch involved in action
contraction, which will be the focus the below section98-100.
Length-Dependent Activation
Cardiomyocytes undergo changes in sarcomere length (SL), the distance
between z-discs, during cell shortening. SL also changes based on ventricular filling
on a beat to beat basis. During diastolic filling the walls of the ventricle stretch, which
physically stretches the cardiomyocytes. The sarcomere responds to this stretch by
sensitizing to calcium and increasing contracility101, 102. This is referred to as lengthdependent activation (LDA) and can happen almost instantaneously, in as short as 5
ms103. LDA is the cellular basis for the Frank-Starling law of the heart, which states that
an increase in end-diastolic volume (EDV) results in an increase in stroke volume104. In
animal models of heart failure and some human patients, LDA and the Frank-Starling
law begins to fail105-108, however this is not consistent among human heart failure
patients107, 109. There are currently no therapeutics to improve the Frank-Starling

mechanism, one of the reasons being that the mechanism by which it occurs has not
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been fully elucidated.
Stretch induces the following alterations to the myofilament lattice110 which are
illustrated in Figure 3: 1) Actin filaments now have room to slide as well as optimal
overlap with myosin heads 2) Lattice spacing, or the distance between thick and thin
filaments, decreases, which increases the chance of myosin binding to actin. 3) The
Proximal Ig and PEVK domains of titin extend, which increases titin-based strain.

Figure 3. Effect of Stretch of Myofilament Organization. Stretch creates several
changes to the sarcomere lattice structure that contribute to increase contractility. 1). At
short SLs, the thin filaments cannot properly move during contraction and there is not
optimal actin and myosin overlap. 2) Lattice spacing or the distance between the thick
and thin filament decreases with stretch, which increases the probability of actin and
myosin binding. 3) At short SLs, the elastic domains of titin are coiled. Stretch induces
an uncoiling of the proximal Ig domains and extension of the PEVK domain, which
increases passive tension.
The complete mechanism(s) by which stretch induces increased calcium
sensitivity is still largely unknown. However, several contributing factors to LDA have
been identified. Beta-adrenergic stimulation induces PKA phosphorylation of TnI (at

S23/24) and cMyBP-C (S273/S282/S302), which enhances LDA, though it has been
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shown that this effect is predominantly via cMyBP-C82. Both TnI and cMyBP-C act as
brakes on their respective interacting partners (TnI on tropomyosin and cMyBP-C on
myosin), and phosphorylation on these residues alleviates this inhibition.
Phosphorylation at pS23/24 on TnI causes a desensitization at both short and long SLs,
however this effect is more pronounced at short SLs, resulting in enhanced LDA111.
Another factor of LDA that has been the focus of much attention is lattice
spacing. Small angle x-ray diffraction studies have been used to provide evidence that
lattice spacing decreases with stretch and places the myofilament head in closer
proximity to actin111, 112. PKA treatment causes an increase in lattice spacing, which
may be due to electrostatic repulsion after the addition of the negative charge111. In
functional experiments, increasing SL results in increased calcium sensitivity113-115. The
increase in calcium sensitivity can be replicated by osmotically compressing the
myofilament lattice with Dextran. This has led to the hypothesis that an increase in SL
causes a decrease in lattice spacing, and this decrease in lattice spacing is what
causes increased calcium sensitivity. However, further work utilizing Dextran
compression has shown that changes in lattice spacing are not always well correlated
with calcium sensitivity104, 112, 116. Therefore, it is likely that while lattice spacing
contributes to calcium sensitivity, it is not the driving factor in LDA.
Titin has been identified as a main component of LDA98, 99, 117, 118. Increases in
passive tension correlate with decreases in lattice spacing, a known contributor to
LDA100, 119. To investigate the role of titin in LDA, several studies have utilized models in
which alterations to titin result in changes to passive tension. Trypsin treatment of titin
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was found to degrade the elastic I-band region, increasing lattice spacing and reducing
both passive tension and LDA in rat trabecular muscle100. Genetic models have also
been used to connect passive tension and LDA. In an N2B KO mouse, which exhibits
increased passive tension, both LDA (in cardiomyocytes) and the Frank-Starling

mechanism (in explanted hearts) was enhanced118. Alternatively, in a rat model in which
a longer isoform of titin is expressed due to mutations in titin’s splicing factor RBM20,
both passive tension and LDA were decreased98. Small angle-diffraction and electron
density (ED) experiments revealed that changes to titin do not alter troponin’s affinity for
calcium, excluding that as a mechanism of enhanced calcium sensitivity. However,
stretch was found to cause a structural rearrangement of both thick and thin filament
proteins. In the presence of the longer, more compliant, titin, this structural
rearrangement fails to happen. This work provides further evidence that titin acts to
transmit strain across the myofilament.
Glycogen Synthase Kinase 3 (GSK-3)
GSK-3 is a ubiquitous Serine/Threonine kinase initially described for its
involvement in the glycogen synthesis pathway5, 120. The GSK3 family is composed of
two isoforms, GSK-3⍺ and GSK-3β, which are encoded by separate genes. While
having 98% homology of their kinase domains, GSK-3⍺ is slightly larger, due to an
additional glycine-rich domain at its N-terminus121 (Figure 4). As the GSK3 family is
ubiquitous and promiscuous, it is perhaps unsurprising that the ⍺ and β isoforms have
been found to have both redundant122, 123 and isoform specific roles 124-126. GSK-3β

became the more prominent isoform of study in many systems and disease models
after it was discovered that germline knockout of GSK-3β is embryonic lethal, primarily

stemming from liver degradation and congenital heart

defects6, 127.

GSK-3⍺ KO mice
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are viable, suffering from comparatively mild metabolic defects128. This has led many to
believe that GSK-3β is able to compensate for GSK-3⍺ more than GSK-3⍺ can
compensate for GSK-3β.

Figure 4. Domain Structure of GSK-3. Graphic depicting differences in GSK-3⍺
and GSK-3β in size and domain structure, as well as phosphorylation sites
(pS21/S9 and pY279/Y216) known to modulate kinase function.

GSK-3β is also thought to be the more relevant isoform in terms of disease
relevancy, being linked to several different types of cancer129, 130, neurodegenerative
diseases such as Alzheimer’s131-133, cardiovascular disease8, 10, 134, diabetes135, and
mood disorders such as Bipolar disorder136. GSK-3β’s wide involvement in different
diseases is attributed to its involvement in signaling pathways that affect proliferation,
hypertrophy, and autophagy- processes that frequently become dysregulated in disease
that are essential for maintaining normal cell physiology137.
GSK-3β is considered to be an extremely prolific kinase, with over 500 proposed
substrates138. Due to its wide array of targets, it is generally agreed upon that GSK-3β
must undergo extensive regulation in order to direct it to specific targets.

Mechanisms Regulating GSK-3β Activity
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GSK-3β is unique in that it is a constitutively active kinase, meaning that at
baseline it is active, able to phosphorylate substrates, and does not need to be
“activated” by a modification137. Post translational modifications on GSK-3β can thus
decrease or further increase its kinase activity.
Another unique aspect of GSK-3β is that it prefers substrates that are preprimed, meaning they are already phosphorylated at a residue C-terminal to GSK-3β’s
target site. Pre-primed phosphorylations typically fit a consensus sequence of
Ser/ThrTarget-X-X-X-pSer/ThrPre-primed site139. The “X” amino acids between these two
residues are typically Prolines, but this can vary. GSK-3β prefers these substrates
because the pre-phosphorylated residue interacts with a positively charged pocket on
GSK-3β created by Arginine and Lysine residues. Binding to this pocket then directs the
target phosphorylation into GSK-3β’s catalytic site.126 Well-described pre-primed
substrates of GSK-3β include glycogen synthase140, tau141, and beta-catenin142.
Multiple priming kinases which target these residues have also been identified143. GSK3β is capable of phosphorylating “non-primed” substrates, however pre-priming of
several of its well described substrates was found to increase its efficiency by a factor
up to 1000X144.
Phosphorylation of GSK-3β on the Serine 9 residue (typically by PKB/Akt)
decreases its affinity for pre-primed substrates and is used as a marker of the kinase’s
activity145. This Serine 9 residue sits in the binding pocket and acts as a competitive
inhibitor to pre-primed substrates. It is important to note that phosphorylation at this

residue does not “turn off” the kinase but directs it towards phosphorylating “non-
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primed” substrates146.
Phosphorylation at GSK-3β’s Y216 site increases its kinase activity. Generation
of the crystal structure of GSK-3β elucidated that Y216 is located in the activation loop
of the kinase and its phosphorylation is believed to open up the loop due to an
interaction with positively charged amino acids147. This residue has also been shown to
be auto-phosphorylated during folding and requires an interaction with HSP90 in order
to form the appropriate conformation for autophosphorylation148, 149. Y216 can be also
targeted by the tyrosine kinases fyn150, protein-tyrosine kinase 2-beta (PYK2)151, and
dual specificity mitogen-activated protein kinase kinase 1 (MEK1)152. As these studies
were performed in vitro and it is unknown how this site is regulated in vivo, and
specifically in the cardiomyocytes.
GSK-3β Cytosolic Signaling
GSK-3β was initially described for its role in the glycogen synthesis pathway
where it acts as a negative regulator of glycogen synthesis. In the absence of insulin,
GSK-3β phosphorylates Glycogen Synthase, which inhibits its kinase activity. Insulin
signaling activates Akt, which phosphorylates GSK-3β at S9 on GSK-3β. This releases
GSK-3β’s inhibition on glycogen synthase, which results in increased glycogen
synthesis5.
GSK-3β has been heavily studied in the context of the Wnt signaling, which is
vital during embryonic development for body patterning and cell migration, fate, and
specification153. In this pathway, the alpha and beta isoforms have been found to have
redundant functions, and both act as negative regulators of beta-catenin. Briefly, GSK-
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3β phosphorylates beta-catenin, and this retains beta-catenin in a destruction complex.
When Wnt signaling is initiated, GSK-3β is inhibited and beta-catenin accumulates in

the cytosol and eventually re-localizes to the nucleus, where it can act as a transcription
factor and drive gene expression.
GSK-3β is also an established negative regulator of cardiomyocyte hypertrophy,
cell growth that can result in the thickening of the heart walls. Hypertrophic gene
expression can be stimulated by calcium-calcineurin induced translocation of the
transcription factor nuclear factor of activated t-cell 5 (NFAT) into the nucleus154. GSK3β negatively regulates this process by phosphorylating NFAT, which causes it to relocalizes out of the nucleus and into the cytosol, where it cannot induce transcription.
Hypertrophy can be either pathological or compensatory/physiological, therefore, many
groups have been interested in manipulating GSK-3β’s expression and or activity to
determine its effect on hypertrophy.
GSK-3β Mouse Models
Starting in the early 2000s, many different types of GSK-3β mouse models were
generated to elucidate GSK-3β’s function in both health and disease. Due to the
differences in animal models (Constitutive versus inducible, global versus
cardiomyocyte specific, the specificities of the disease model), it is difficult to make
large generalizations about GSK-3β’s effect. Most certainly, GSK-3β can be both
beneficial or harmful, depending on context. These studies will be expanded upon
below and summarized in Table 2.

Impact on Normal Heart Function
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As stated above, germline knockout of GSK-3β is embryonic lethal, with a main
cause of death being destruction of the ventricular cavities by hyperproliferative cells6.
As manipulation of GSK-3β must occur after development, many groups have utilized
inducible models. Additionally, as GSK-3β is ubiquitous, researchers have turned to
cardiomyocyte specific knock-out or knock-in models. Germline GSK-3β KO was
harmful due to dysfunctional cardiomyocyte growth, and it was hypothesized that
cardiomyocyte-specific overexpression would also lead to dysfunction, potentially from
impaired growth. A 9-fold increase of GSK-3β in an overexpression model did in fact
cause decreased cardiomyocyte size, and ventricular growth, and thinned ventricular
walls8. Aside from the hypothesized effects on cardiomyocyte growth, GSK-3β
overexpression also slowed relaxation, which was determined to be caused by
decreased sarcoplasmic/endoplasmic reticulum calcium ATPase3 (SERCA2A)
expression. These experiments reveal that a fine balance of GSK-3β is required for
heart growth and function.
Impact on Disease
It was hypothesized that the hyperproliferative effects of GSK-3β KO could be
beneficial in an MI model, where the heart becomes weakened due to cardiomyocyte
loss. Post MI, cardiomyocyte specific GSK-3β KO mice had improved ventricular
function post MI compared to littermate controls 9. Therefore, in this context GSK-3β KO
was protective. GSK-3β KO was also investigated in the context of a pressure overload
model in which GSK-3β KO mice underwent trans-aortic constriction (TAC), which is
used to induce pathological hypertrophy9. Surprisingly, despite GSK-3β’s well described

role as a negative regulator of hypertrophy, knockout of GSK-3β did not exacerbate
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hypertrophy, and was found to have no effect.
Other groups have utilized mouse models which target not just the presence or
absence of GSK-3β, but its kinase activity. Overexpression of dominant negative GSK3β results in decreased kinase activity and improved cardiovascular function post
induction of pressure-overload13 12, 155.
Expression of constitutively active GSK-3β has also been found to be protective
in certain contexts. Double-knock in of constitutively active GSK-3β and GSK-3⍺ was
protective against hypertrophy and fibrosis induced by chronic adrenergic stimulation156,
but not after MI157. A different constitutively active GSK-3β mouse model has been used
to study the role of GSK-3β activity in ischemia-reperfusion injury. After a MI, the heart
becomes weakened due to loss of contractile tissue, but there is also additional injury
that stems from transitioning from a state of ischemia to reperfusion, which leads to
mitochondrial damage due to increased production of reactive oxygen species,
depletion of ATP, and accumulation of calcium in the mitochondrial matrix. Transgenic
S9A of GSK-3β was beneficial in an ischemia-reperfusion model. This was attributed to
improving mitochondrial function158, however this effect was not replicated in other
ischemia/reperfusion studies159.
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Table 2. GSK-3β Mouse Models. Outline of the different GSK-3β mouse models,
heart disease model that have been used to study, effect of GSK-3β’s altered
expression and activity on disease progression, and the proposed reason for these
findings. Adapted from Lal et al, 2015.
Mouse Line
GSK-3β Global
KO

Model
-

Main finding
Detrimental

TAC

-

-

Detrimental

MI

Beneficial

TAC

Beneficial

I/R

Both Detrimental
and Beneficial

GSK-3β S9A

TAC

Beneficial

Cardiomyocyte
Specific GSK-3β
S9A

TAC

Beneficial

Cardiomyocytespecific GSK-3β
S9A

I/R

Detrimental

GSK-3β
cardiomyocytespecific KO
Cardiomyocyte
specific Tg-GSK3β
Cardiomyocyte
specific GSK-3β
KO
Cardiomyocyte
specific Dominant
negative GSK-3β
Dominant negative
GSK-3β

Description of model
Embryonic lethal; Degradation
of the liver; hyperproliferation
of the heart resulting in
impaired ventricular chambers
Did not protect against
hypertrophy

Reference
Hoeflich et
al, 2000127;
Kerkela et
al, 20086
Woulfe et
al, 20109

Decreased cardiomyocyte
growth; thinned ventricular
walls; impaired diastolic
function
Reduced dilation of the
ventricle and improved global
heart function
Decreased apoptosis and
fibrosis

Michael et
al, 2004160

Exacerbation of ischemic
injury and improvement of I/R
injury
Lessened hypertrophy and
improved systolic function
Lessened hypertrophy

Zhai et al,
201210

Exacerbated mitochondria
disfunction

Gomez et
al, 2008158

Woulfe et
al, 20109
Hirotani et
al., 200713

Matsuda, et
al., 200812
Antos et al.,
2002155

GSK-3β at the Sarcomere
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Interaction with cMyBP-C
GSK-3β has more recently been studied in the context of the myofilament. In an
in vitro study GSK-3β was found to phosphorylate a residue (Ser 133) on cardiac
cMyBP-C in human heart tissue161. cMyBP-C contains domains that interact with both
the thick and thin filaments, and regulates cross-bridge cycling kinetics162, 163, and it has
been previously found that these kinetics can be modulated by phosphorylation164.
Phosphorylation of S133 was decreased in human heart failure patients compared to
non-failing controls. Additionally, treatment of skinned myocytes isolated from heart
failure patients with reduced pS133 with recombinant GSK-3β increased the rate of
force redevelopment. This work identified a potential mechanism by which GSK-3β can
phosphorylate and influence myofilament function.
GSK-3β and Cardiac Dyssynchrony
Dyssynchrony occurs when there is a contractile delay between opposing walls
of the ventricle. This reduces the amount of blood that is ejected from the heart during
each contraction and can greatly worsen function in patients already suffering from
heart failure165. Dyssynchrony can occur from a conduction abnormality, typically a
bundle branch block, or as a result of tissue death (ischemia-induced dyssynchrony)166,
in which the damaged area becomes weaker and cannot contract as strongly. The most
effective treatment for cardiac dyssynchrony is called Cardiac Resynchronization
Therapy, or CRT, which paces the heart back into synchrony. A study was performed in
a dog model to investigate changes the myofilament undergoes during disease (heart
failure with dyssynchrony) and treatment (CRT). Phospho-proteomics identified a group
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of proteins in which phosphorylation decreased during dyssynchronous heart failure and
increased with CRT therapy. Many of these residues were predicted to be targets of
GSK-3β and several of these sites were verified by in vitro GSK-3β treatments
experiments. Functionally, skinned myocytes from dogs with dyssynchronous heart
failure had reduced calcium sensitivity, and this was rescued by treatment with
recombinant GSK-3β. This work was vital to identifying a role for GSK-3β at the
myofilament, however the GSK-3β specific work was all done in vitro.

CHAPTER 3
GSK-3β LOCALIZES TO THE MYOFILAMENT VIA PHOSPHORYLATION AT Y216
Introduction
GSK-3β is a prolific cytosolic kinase with over 500 proposed substrates138.
Therefore, it must undergo substantial regulation in order to maintain substrate
specificity. One proposed mechanism by which this may occur is that GSK-3β localizes
to different subcellular compartments where it can then target specific substrates. In
addition to the cytosol, GSK-3β has been found to localize to the nucleus167-170,
mitochondria171, 172, and lipid microdomains173. Changes in its localization, specifically
to the mitochondria, have been connected to stress and injury167, 168, 171, 174 in the heart.
In addition to substrate specificity dependent upon subcellular localization, GSK3β may also be regulated by its own phosphorylation sites. GSK-3β prefers pre-primed
substrates, or substrates that already have a phosphorylated residue downstream of its
target residue126. Phosphorylation at the S9 residue blocks GSK-3β’s pre-primed
binding pocket, reducing its affinity for pre-primed substrates. This phosphorylation site
is typically used as a marker for its kinase activity, however, it may also serve to shift
GSK-3β’s substrate preference to non-primed substrate. Phosphorylation at the Y216
residue increases GSK-3β’s kinase activity through opening of the kinase loop126.
Additional phosphorylations sites on GSK-3β have also been identified175, as well as
other post-translational modifications176, 177. Therefore both localization and
32

phosphorylation should be taken into consideration when exploring GSK-3β’s capacity
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to influence signaling pathways7.
Several different mouse models have been developed as tools to investigate how
GSK-3β contributes to cardiovascular function in health and disease. These models
include germline deletions, inducible knockouts, tissue-specific knockouts, and
overexpression models178. An overarching theme of what has been gained from these
models is that GSK-3β can be protective, harmful, or have no effect in heart failure178.
Perhaps one of the reasons that there is so much disparity is because GSK-3β performs
different functions in health and disease, and these functions may be specific to
different subcellular compartments. When these fractions are looked at as a whole as
opposed to individually, changes in GSK-3β expression or activity may not be
identifiable.
Over the course of the past ten years GSK-3β’s myofilament localization has
begun to be explored. Utilization of animal models of heart failure, in vitro studies, and
tissue from human heart failure patients has made it clear that GSK-3β has the ability to
phosphorylate myofilament proteins, impact myofilament function, and be clinically
relevant in heart failure14, 164, 179. There are several lines of evidence that GSK-3β can
localize directly to the myofilament. In vitro experiments in which the cardiac
myofilament has been incubated with recombinant, active GSK-3β resulted in increased
myofilament calcium sensitivity (in a dog model of heart failure)14 and an increased rate
of cross-bridge re-development, or Ktr (in human heart failure)161. In these preparations,
cardiomyocytes are skinned to permeabilize the membrane, and the cytosolic contents
are washed away. As the cytosolic contents are removed, it is presumed that GSK-3β is

modulating myofilament function via a direct interaction with myofilament proteins and
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not through an upstream signaling mechanism. However, immunofluorescence was not
performed in conjunction with these experiments to determine where within the
myofilament the recombinant GSK-3β localized. In addition, in vitro phospho-proteomics
in which skinned myocytes were treated with recombinant GSK-3β and radio-labeled
ATP revealed that GSK-3β, presumably at saturating concentrations, is capable of
directly phosphorylating several myofilament proteins14.
The ability of GSK-3β to localize to and phosphorylate the myofilament in vivo
has never been shown. Being able to identify where within the myofilament it localizes
as well as what myofilament proteins GSK-3β phosphorylates is important for
understanding how GSK-3β modulates function. The objective of this study was to
identify if an independent subcellular myofilament pool exists, where within the
myofilament this pool localizes, and if myofilament GSK-3β could phosphorylate
myofilament targets. We hypothesized that GSK-3β can localize to the myofilament and
phosphorylate myofilament proteins in vivo. We first explored GSK-3β’s ability to
localize to the myofilament by probing for GSK-3β in left ventricle tissue enriched from
the myofilament. Immunofluorescence of human non-failing left ventricular myocytes
was used to identify where within the myofilament GSK-3β localizes, as well as if GSK3β’s own phosphorylation was important for localization. This was expanded upon using
phospho-mutants of these sites expressed via adenovirus in neonatal rat ventricular
cardiomyocytes (NRVMs). Finally, we utilized cardiomyocyte specific, inducible GSK-3β
KO mice to assess the ability of GSK-3β to phosphorylate myofilament substrates in
vivo. We found that GSK-3β can indeed localize to the myofilament, specifically at

cardiac z-discs. This localization is driven by phosphorylation at GSK-3β’s own Y216
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residue. From our phospho-proteomics experiment, we identified several myofilament
proteins that are targets of GSK-3β in vivo.
Methods
Human Tissue Collection
Human study protocols were approved by the IRB at the Cleveland Clinic and
Loyola University Chicago. All patients gave informed consent.
Tissue Preparation
To prepare whole tissue lysates, left ventricular tissue (human and mouse) was
homogenized in lysis buffer (in mM: 50 Tris pH 7.5, 150 NaCl, 1% Triton X-100)
supplemented with protease and phosphatase inhibitor cocktails (Thermo Fisher
Scientific). Samples were then sonicated and centrifuged at 15,000xg for 10 minutes.
To prepare myofilament enriched samples, left ventricular tissue (human and mouse)
was skinned by homogenization in standard relax buffer (SRB) (in mM: 75 KCL, 10
Imidazole, 2 MgCl2, 2 EDTA, 1 NaN3) with 0.3% Triton X-100 supplemented with
protease and phosphatase inhibitor cocktails (Thermo Fisher). Samples were
centrifuged at 15,000xg for 1 minute and the supernatant was discarded. The pellets
were triturated in SRB with triton, centrifuged, and the supernatant discarded. The
pellets were then washed twice by triturating with SRB without triton, centrifuged, and
the supernatant was discarded. The pellets were solubilized in 8M urea, sonicated, and
centrifuged at 15,000xg for 10 minutes to clarify. Protein concentrations were quantified
via bicinchoninic acid protein assay (BCA) (Pierce).

Western Blot
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Equal amounts of sample were loaded onto 4-12% Bis-Tris gradient gels (Bolt)
and transferred to nitrocellulose membrane. Membranes were incubated in blocking
buffer (Licor) for one hour, and primary antibody overnight at 4°C. Blots were washed
with TBS-T and incubated in infrared red dye conjugated secondary antibodies (Licor) at
room temperature for one hour in the dark prior to being imaged on an Azure C600 infared imager at 700 and 800 nm. Signal intensity was quantified on Azure analysis
software.
Immunofluorescence
Human or mouse LV was homogenized in isolation solution (see above) with
0.3% triton, with protease and phosphatase inhibitors (1:100). Cells were plated onto
chamber slides coated with Poly-L-lysine solution (Millipore Sigma, P4707) and allowed
to adhere for 20 minutes. Cells were fixed with ice cold methanol for 1 minute, and then
4% paraformaldehyde (PFA) for 3 minutes. To skin, cells were washed twice with PBS
with 0.5% Triton X-100 for 20 minutes each, followed two washes in PBS with 0.1%
Triton for 15 minutes. The samples were then incubated in antigen-retrieval solution (0.1
M Glycine, pH 7.4) for 30 minutes. After washing three times with PBS, the slides were
incubated for 30 minutes at room temperature in blocking solution (1% BSA in PBS)
diluted 1:1 with PBS. Primary antibody was diluted in blocking solution, and incubated
with primary antibody overnight at 4°C. The following day, slides were washed three
times with PBS, and incubated with secondary antibody, Alexa Fluor 488 and 568,
(Thermo Fisher Scientific) diluted in blocking solution at room temperature for one hour.
Slides were then washed with PBS and mounted with hard-set Vectashield with DAPI

(Vectashield) and stored in the dark prior and post imaging. Slides were imaged on a
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Zeiss LSM 880 Airyscan with a 40X oil objective. To test for non-specific binding, both
human and mouse myocytes were incubated with (1) both rabbit and mouse IgG at a
concentration which matched those of primary antibodies used (followed by incubation
with incubation with Alexa Fluor 488 and 568 secondary antibodies or (2) Alexa Fluor
488 and 568 secondary antibodies in the absence of primary antibodies. This imaging
was performed in parallel with imaging of GSK-3β and α-actinin specific primary
antibodies and imaging conditions (laser power and gain) were kept constant across
imaging of control slides (Appendix A. Figures A-B).
Recombinant GSK-3β Treatments
Three doses of alkaline phosphatase (Millipore, A2356) were prepared: 0.1, 1,
and 4 DEA units. The phosphatase was added to 0.2 µg each of recombinant HIStagged GSK-3β (Millipore, G4296) and incubated at 37°C for twenty minutes. A baseline
control in which the alkaline phosphatase buffer (50% glycerol containing 5 mM Tris, 5
mM MgCl2 and 0.1 mM ZnCl2, pH 7.0) was added to the GSK-3β was used. Western
blot was then used to quantify total GSK-3β and pY216 GSK-3β. For
immunofluorescence experiments, a baseline recombinant GSK-3β + buffer and
recombinant GSK-3β + 4 DEA units of alkaline phosphatase were prepared as just
described. After incubation at 37°C, the GSK-3β was added to wildtype mouse skinned
myocytes (as described in the immunofluorescence protocol). Cells were incubated with
the recombinant GSK-3β at room temperature, with rotation, for 20 minutes prior to
adherence to slides. The immunofluorescence protocol described above was then

followed for fixing, blocking, and incubation with primary and secondary antibodies. ⍺-
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actinin (Millipore, A2543) and HIS (Cell Signaling, 2366).
Coimmunoprecipitation

Myofilament enriched samples from human non-failing LV (n=5) were used for
these experiments. To bind the antibody to the beads, 10µg of antibody: (GSK-3β (Cell
Signaling Technology, 12456), GSK-3β pS9 (Cell Signaling Technology, D28E12),
GSK-3 (Y279/Y216 (EMD Millipore, 05-413) diluted in PBS-T were combined with 50 µl
of Dynabeads Protein G (Thermo Fisher Scientific) and incubated with rotation, at room
temperature, for 10 minutes. The beads were then separated from supernatant with a
magnetic stand, and the supernatant was discarded. Beads were gently washed in
PBS-T. To allow binding of protein to the antibody-conjugated beads, 400 µg of protein
was added to the beads and incubated with rotation for 10 minutes at room
temperature. The supernatant was kept to run as the flow-through fraction. The beads
were then gently washed 6 times with PBS-T. After the final wash, the beads were
suspended in loading buffer and boiled, and the eluted supernatant was loaded on a 412% Bis-Tris gel (Bolt) with the corresponding flow-through fractions. The gels were
then fixed and silver-stained (BioRad). The reaction was stopped with 5% acetic acid
when the background became saturated.
Adenovirus
WT mouse GSK-3β (NM_019827) was purchased from Origene (Cat:
MR206669) and 216 F and E oligonucleotides were purchased from IDT. Y216F and
Y216E were subcloned into the WT GSK-3β plasmid using standard methods. The WT
GSK-3β contained a c-terminal Myc tag, and the two mutants contained c-terminal Flag
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and Myc tags. Adenoviruses were generated using the Agilent Adeasy XL system (cat #
240009) following manufacturer protocols. Viruses were CsCl purified prior to dialysis
and use.
Neonatal Rat Ventricular Cardiomyocytes (NRVM) Isolation
NRVMs were isolated from 1-day old rat pups. Hearts were digested with trypsin
and collagenase, using the Worthington Neonatal Cardiomyocyte Isolation System
(Worthington). Cells were plated and allowed to incubate at 37⁰C for 24 hours prior to
continuing experiments.
NRVM Viral Overexpression
NRVMs were infected with either wild type GSK-3β, GSK-3β Y216F, GSK-3β
Y216E, or an empty control vector. Samples incubated for 24 hours before harvest. A

portion of the cell lysate was used for immunoblotting (as described above) to verify and
quantify the overexpression. The primary antibodies were as follows: GSK-3β (Cell
Signaling Technology, 12456), GSK-3β pS9 (Cell Signaling Technology, D28E12),
GSK-3 (Y279/Y216 (EMD Millipore, 05-413)) and tag antibodies: Myc tag (Cell Signaling
Technology, 2278) and Flag tag: (Cell Signaling Technology, 8146).
Prior to performing co-immunoprecipitation experiments, cells were skinned in
0.3% triton for 15 minutes. The samples were centrifuged and washed twice with PBS,
and then solubilized in 8M urea. The samples were then sonicated and centrifuged. Coimmunoprecipitation was performed as described above, with the myc-tag antibody
used to pull down proteins, as this tag was found on all three virus constructs. A subset
of the cell lysis was incubated with beads that lacked antibody, to control for non-

specific binding. The eluted samples and flow-throughs were run on a 4-12% Bis-Tris
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gel and silver-stained.
GSK-3β KO Mice
Cardiomyocyte-specific, conditional GSK-3βflox/flox, α-MHC Mer Cre Mer (MCM) +
mice9 (a kind gift from Dr. Thomas Force and rederived at Jackson Laboratories) and
littermate controls, GSK-3β flox/flox α-MHC MCM -, were generated from several crosses
of GSK-3β flox/flox and α-MHC Mer Cre Mer (MCM) strains, both on the C57BL/6J
background. Mice were backcrossed with wild type C57BL/6J mice every 10-12
generations. Approximately equal numbers of male and female mice, age 12-14 weeks,
were used in all experiments.
At 10 weeks of age both male and female mice began tamoxifen chow diet (250
mg/kg Envigo TD.130855) for 5 consecutive days followed by two days of regular chow
to maintain body weight, repeated for 3 weeks total. B and M-mode blinded
echocardiography was performed (Vevo 2100, Fujifilm Visualsonics) prior to and
following knockdown to detect any impact of the tamoxifen on global heart metrics such
as ejection fraction and fractional shortening. All procedures were approved by the
Loyola Animal Care and Use Committee.
Mass Spectrometry
Left ventricle (LV) tissue from Con (n=4) and GSK-3β KO (n=5) mice were
enriched for the myofilament, digested in trypsin, desalted, and phospho-enriched using
titanium oxide beads. Samples were analyzed by LC-MS/MS using Data-Independent
Acquisition (DIA) (Orbitrap Fusion Lumos Tribrid Mass Spectrometer). Data were
processed using DIA-Umpire and then underwent Median-based normalization.
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Statistics
Variables are expressed as mean ± standard error. Statistical significance was
calculated in GraphPad Prism (version 9) by t-test, one-way analysis of variance, or

two-way analysis of variance followed by the Tukey or Mann-Whitney post-hoc tests, as
indicated. Normality (by Shapiro Wilk test) and equal variance (by F-test for t-tests or
Brown-Forsythe test for ANOVAs) were tested prior to all parametric tests. P-values
less than 0.05 were considered statistically significant.
Results
GSK-3β Localizes to the Cardiac Z-Disc
In order to determine if GSK-3β can localize to the myofilament, we performed
fractionation of left ventricles of wild type mice into myofilament and soluble fractions.
Additionally, we prepared a lysis of the ventricle that incorporated both fractions, a
whole tissue lysis. These preparations were used for two experiments- tissue was
resolved on an SDS-page gel and 1) stained with Coomassie to visualize differences in
the preparations as well as 2) transferred and blotted for myofilament and soluble
proteins. GSK-3β was identified in both myofilament and soluble fractions, as well as a
whole tissue lysis (which contains both fractions) (Figure 5A-B). The cleanness of the
myofilament enrichment can be evidenced by the lack of GAPDH, a cytosolic protein, in
the myofilament enrichment lanes. Alternatively, Troponin I, a myofilament protein, is
found primarily in the myofilament enrichment prep and only modestly in the whole
tissue lysis. GSK3 (GSK-3⍺ and GSK-3β) are seen in all three preparations, indicating
that they localize to both cytosolic fractions as well as the myofilament. In addition, the
band in the myofilament enrichment is prominent.
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Figure 5. Myofilament Preparation of Left Ventricle Myocardium Enriches for
Myofilament Proteins While Excluding Cytosolic Contents. (A) Coomassie stained
SDS-Page gel depicting left ventricle prepared as whole tissue lysis (W), soluble
fraction (S), myofilament enrichment (M) (B) Western blot of W, S, and M samples
blotted for GSK-3, GAPDH, and Troponin I (TnI).
In order to gather further insight into where GSK-3β was localizing within the
myofilament, we performed immunofluorescence experiments. Myocytes from the left
ventricle of non-failing human patients were permeabilized, and the cytosolic contents
were washed away, exposing the myofilament. Three different GSK-3β antibodies, one
for total GSK-3β and two for its phosphorylated forms (pS9 and pY216) were used. As
these two phosphorylation sites cause changes in the activity of GSK-3β, we
hypothesized that this could potentially cause changes in its localization. We found that
GSK-3β localizes to the z-disc, as it co-localizes with ⍺-actinin (Figure 6). Particularly,
GSK-3β phosphorylated at pY216 had the most distinct z-disc localization. The z-disc
localization of GSK-3β in the pS9 probed cells was very faint but can be seen on the
signal-intensity plots. The total GSK-3β probed cells also had a distinct z-disc pattern,
however this was fainter than the pY216 cells. This is unsurprising, as we would
anticipate the total GSK-3β antibody binds to GSK-3β phosphorylated at both pS9 and
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pY216. Therefore, if pY216 is driving the z-disc localization, this would also be present
with the total GSK-3β antibody.

Figure 6. GSK-3β Localizes to the Z-Discs in Human Non-Failing Skinned
Cardiomyocytes. Representative immunofluorescence in skinned cardiomyocytes in
which GSK-3β (green) has been probed for with three antibodies: total GSK-3β, pS9
GSK-3β, and pY216 GSK-3β. ⍺-actinin, which demarcates the z-disc, is depicted in
red. Scale bars on the merged images are 10 µm. Signal intensity plots depict ⍺actinin (red) and GSK-3β (green), representing the colocalization of actinin and GSK3β.

As we found that the pY216 antibody had the strongest z-disc co-localization, we
wanted to test if de-phosphorylation of this residue would cause GSK-3β to localize
away from the z-disc. We first needed to determine if we could reduce pY216
phosphorylation with phosphatase treatment. We treated recombinant GST-tagged
GSK-3β (0.2 µg) with increasing amounts of alkaline phosphatase (0, 0.1, 1.0, and 4
units). We found that 1.0 and 4.0 units of phosphatase significantly decreased
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phosphorylation at Y216 (n=3; 0 vs 1 units p=0.023, 0 vs 4 units p<0.0001 by One-way
ANOVA with multiple comparisons) (Figure 7A-B). We next tested whether 1)
recombinant GSK-3β would localize to the z-disc when incubated with skinned

myocytes and 2) if alkaline phosphatase treated GSK-3β would impact this localization.
We treated wild type mouse skinned myocytes with either 0.2 µg of GSK-3β or 0.2 µg of
GSK-3β pre-treated with 4 units of alkaline phosphatase. Cells were then fixed and
probed with ⍺-actinin (to delineate the z-discs) and GST-tag (to identify recombinant

GSK-3β) antibodies. In the absence of alkaline phosphatase, the GST signal (red)

colocalized with ⍺-actinin (green) (Figure 7C-D). Pre-treatment of the recombinant

GSK-3β with alkaline phosphatase decreased the intensity of the GST-signal compared
to the ⍺-actinin peak.
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Figure 7. Treatment of Recombinant GSK-3β with Alkaline Phosphatase Alters
Z-Disc Localization. (A) 0.2 µg of recombinant His-tagged GSK-3β was treated with 0,
0.1, 1.0, or 4.0 units of alkaline phosphatase. Total GSK-3β (green) and pY216 GSK-3β
(red) was visualized via western blot. (B) Quantification of pY216/total GSK-3β in
alkaline phosphatase treated recombinant GSK-3β (n=3; 0 vs 1 units p=0.023; 0 vs 4
units p<0.0001 calculated by One-way ANOVA with repeated measures). (C) Wild type
mouse skinned myocytes treated with His-tagged recombinant GSK-3β (baseline) or
His-tagged recombinant GSK-3β that was pre-treated with 4 units of alkaline
phosphatase (phosphatase). Cells were probed with antibodies for ⍺-actinin (green) and
His (red). Scale bars = 10 µm. (D) Representative signal intensity plots depicting alphaactinin (green) and His (red).
Previous work in a disease model found that GSK-3β localizes to the intercalated
disc in disease179, and we noticed a potential intercalated disc staining in the
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immunofluorescence experiments in which we counter-stained with ⍺-actinin. Therefore,
we performed immunofluorescence experiments in which we probed for GSK-3β and

counterstained with the intercalated disc protein N-cadherin (Figure 8). We found that
total GSK-3β, pS9, and pY216 GSK-3β all co-localized with N-cadherin, indicating that
this protein can localize to the intercalated disc regardless of its phosphorylation status.

Figure 8. GSK-3β Localizes to the Intercalated Disc in Non-Failing
Cardiomyocytes. Representative immunofluorescence in skinned cardiomyocytes in
which GSK-3β (green) has been probed for with three antibodies: total GSK-3β, pS9
GSK-3β, and pY216 GSK-3β. N-cadherin, which localizes to the intercalated disc, is
depicted in pink. Scale bars on the merged images are 10µm.
Phosphorylation at Y216 Increases GSK-3β’s Affinity for the Myofilament
The immunofluorescence experiments suggest that phosphorylation at Y216 is
important for GSK-3β’s myofilament localization. To further explore this hypothesis, we
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performed immunoprecipitation experiments in human NF LV myofilament enrichments.
Pulling down with total GSK-3β, pS9, and pY216 antibodies as bait, we ran the eluted
proteins on a gel using SDS-page, and then silver-stained the gel to visualize the
proteins (Figure 9A). We found that total and pS9 GSK-3β did not pull-down
myofilament proteins, while pY216 GSK-3β showed high levels of the primary
myofilament proteins. Because of the strong association of myofilament proteins for
each other, this result does not indicate a specific binding partner of pY216 GSK-3β,

simply that pY216 GSK-3β has a stronger affiliation than the total and S9 antibodies. As
total GSK-3β should include pY216 GSK-3β, it was surprising there was little interaction
between total GSK-3β and the myofilament. One explanation is that Y216
phosphorylation makes up a small percentage of total GSK-3β, however, it is also
possible this is due to differences between the primary antibodies.
To confirm whether phosphorylation at Y216 is necessary and sufficient for GSK3β’s association with the myofilament, we generated myc-tagged adenoviruses (so the
same primary antibody could be used in each) for wildtype (WT) GSK-3β, phospho-null
(Y216F) GSK-3β, and phospho-mimetic (Y216E) GSK-3β and transduced them into
neonatal rat ventricular myocytes (NRVMs). Probing for the myc-tag revealed equal
expression in the transduced NRVMs (Figure 9B-C). Co-immunoprecipitation in
myofilament-enriched samples showed Y216E GSK-3β strongly bound to the
myofilament, while almost no binding was observed with the phospho-null Y216F GSK3β (Figure 9D-E). A modest amount of myc-WT GSK-3β also associated with the

myofilament, which we attributed to endogenous Y216 phosphorylation, as shown by
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western blot (Figure 9F).

Figure 9. GSK-3β Associates with the Myofilament Which is Mediated by Y216
Phosphorylation. (A) Silver-stained gel depicting flow-through (FT) and eluted
immunoprecipitation (IP) for myofilament enriched NF sample co-immunoprecipitated
with either total, pS9 or pY216 GSK-3β antibodies. Labels on the right correspond to
hypothesized myofilament proteins and molecular weights. (B) Example western blot
for cMyc for Con (un-transduced) NRVMs and those transduced with Myc-tagged WT
GSK-3β (WT), Y216F, and Y216E. (C) Summary data from data in panel B, means ±
SEM (n = 6/group). P-values were calculated via ordinary one-way ANOVA with
Tukey’s multiple comparisons. (D) silver-stained gel depicting co-immunoprecipitation
of proteins pulled down with a myc tag antibody in Con, WT, Y216F, and Y216E
groups. (E) Summary data of co-IP experiment, showing total lane intensity (mean ±
SEM) (n = 4/group, statistics by non-parametric one-way ANOVA (Kruskal Wallis) with
Dunn’s multiple comparisons). (F) Representative western blot from panel E, depicting
total GSK-3β, pY216, and actin in myofilament enriched NRVMs.
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GSK-3β Phosphorylates Z-Disc Proteins

We utilized a cardiomyocyte-specific inducible GSK-3β knockout mouse (GSK-3β
flox/flox α-MHC

MCM +) to assess whether GSK-3β phosphorylates the myofilament in

vivo. GSK-3β flox/flox α-MHC MCM- mice were used as littermate controls. Both male and
female mice were used for all experiments, and knockout was induced with tamoxifen
chow when mice were nine weeks of age. Fourteen days after tamoxifen was removed,
echocardiography was used to assess global cardiovascular function prior to the
animals being euthanized and collection of heart tissue. Tamoxifen has been found to
depress cardiovascular function180, 181, which could confound our results, therefore a
subset of animals were also echoed prior to tamoxifen to verify that the tamoxifen itself
did not suppress function. We found that this concentration of tamoxifen did not depress
ejection fraction or fractional shortening, metrics of systolic function in either CON or KO
mice (Table 3).
Table 3. Effect of Tamoxifen Injections of Global Heart Function in Control Mice,
Assessed by Echocardiography. “Pre” denotes measurements preformed prior to the
mice being treated with tamoxifen, and “post” denotes measurements performed
fourteen days following conclusion of tamoxifen treatments. EF= ejection fraction; FS=
fractional shortening; LV mass AW = left ventricular mass of the anterior wall. P-values
represent paired t-test between pre and post values.

EF (%)

FS (%)

LV Mass AW
(mg)

PRE

59.05 ± 2.25

31.08 ± 2.91

162.76 ± 30.41

55.06 ± 5.92

22.97 ± 3.82

POST

61.10 ± 2.82

32.37 ± 2.27

164.238 ± 14.97

62.87 ± 2.72

24.45 ± 2.38

P-Value

0.734

0.720

0.962

0.354

0.805

LV Vol;d (ul)

LV Vol;s (ul)
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To evaluate knockdown efficiency, we prepared two sets of protein samples from
the LV, those processed from whole tissue and those enriched for the myofilament. We
detected significant GSK-3β in the myofilament-enriched samples from GSK-3βfl/fl/Cretamoxifen-treated control mice (Con) (Figure 10A) further suggesting there is a pool of
GSK-3β which localizes to the myofilament. In the GSK-3βfl/fl/Cre+ tamoxifen-treated
knockout mice (KO), there was an ~70% reduction in GSK-3β in both the whole tissue
and myofilament-enriched samples (Figure 10B-C). We also detected GSK-3β
phosphorylated at S9 and Y216 (Figure 10D-G) in myofilament enriched and soluble
samples. There was a trending decrease in pS9 (p=0.0568) at the myofilament in the
GSK-3β KO mice that was not present in the whole tissue lysis preparation.

51

Figure 10. Characterization of Inducible, Cardiomyocyte-Specific GSK-3β KO
Mice. (A) Example western blots of GSK-3β in LV whole tissue lysis (top) and
myofilament-enriched (bottom) samples from GSK-3β knockout (KO) and littermate
control (CON) mice. Total GSK-3β, pS9 GSK-3β, pY216 GSK-3β, tubulin, and actin
are depicted. GSK-3β is significantly reduced in both (B) myofilament (n =9-10;
p<0.000001) and (C) whole tissue lysis (n= 6; p=0.002) preparations.
Phosphorylated GSK-3β pS9 at the (D) myofilament and (E) whole tissue lysis, both
normalized to total GSK-3β (n=9). Phosphorylated GSK-3β at Y216 at the (F)
myofilament and (G) whole tissue lysis, both normalized to total GSK-3β (n=6-10).
P-values were determined by unpaired t-test.

To determine if GSK-3β can phosphorylate myofilament proteins in vivo, we
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phospho-enriched myofilament enriched tissue from the LV of CON (n=4) and GSK-3β
KO (n=5) mice, and then performed a mass spectrometry analysis. GSK-3β is a prolific
kinase with known cytosolic targets, and to make sure that the abundance of these
phosphorylations did not cover signal from myofilament proteins we performed these
experiments on tissue enriched for the myofilament. We identified 981 phospho-sites on
305 proteins. Using cutoffs of p < 0.05 and log2Fold Change (FC) < -0.5, we found
decreased phosphorylation at 9 S/T residues on 8 proteins in the KO mice, including the
structural z-disc protein actin binding LIM domain protein 1 (abLIM-1)182, and z-disc
affiliated proteins Supervillin183, Synaptopodin184, and Striated muscle-enriched protein
kinase (SPEG)185 (Figure 11A-B), suggesting they are GSK-3β targets. Two
phosphorylation sites increased (log2FC>0.5), heat shock protein beta-6 (HSPB6) and
Band 3 anion transport protein (B3AT), a plasma membrane protein. We did not detect
changes in phosphorylation of any proteins known to impact calcium sensitivity, even
though GSK-3β was found to increase calcium sensitivity in vitro14.
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Figure 11. GSK-3β Targets Myofilament Substrates. (A) Volcano plot depicting
phosphorylation sites in CON (n=4) and GSK-3β KO (n=5) mice identified by mass
spectrometry. Cut-offs for p-value are displayed at p=0.05 and for a fold change of a
30% decrease. (B) Significantly downregulated and upregulated sites. Proteins shown
to localize to the z-disc are color coded to their respective points on the volcano plot.
The mass spectrometry results indicated GSK-3β targets several proteins at the
z-disc in vivo, so we decided to determine if we could measure changes in general
Ser/Thr z-disc phosphorylation via immunofluorescence. Using LV skinned myocytes
from CON and KO mice (n=3) we probed for ⍺-actinin and pSer/Thr (Figure 12). As a

positive control for reduced phosphorylation, a subset of CON myocytes was incubated
with alkaline phosphatase. Using ImageJ, we set a threshold for the ⍺-actinin channel to
delineate the z-disc, creating a region of interest along the z-discs. We then set this
region of interest as a mask along the pSer/Thr channel the quantify the average
pSer/Thr signal intensity. The signal intensity (normalized to the actinin area) of z-disc
pSer/Thr staining significantly decreased in GSK-3β KO mice compared to Con animals
(p=0.0091). Decreased phosphorylated z-disc area was also observed in cells
incubated with alkaline phosphatase (p=1.0 X 10-6). It should also be noted that the

pSer/Thr signal also appeared to decrease in areas outside of the z-disc, which is
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unsurprising, as other proteins were identified as GSK-3β targets in the phosphoproteomics screen.

Figure 12. GSK-3β Phosphorylates Z-disc Proteins. Representative
immunofluorescence from CON and GSK-3β KO LV tissue in which samples were
probed for the z-disc marker ⍺-actinin (red in merged image) and phosphorylated
Serine/Threonine residues (green in merged image). A subset of CON tissue was preincubated with alkaline phosphatase to act as a positive control (Phosphatase). Scale
bar = 5 µm (2 µm in enlarged images). Yellow arrows delineate z-discs. Quantification
of Z-disc average signal intensity of pSer/Thr staining (normalized to control). n=3 mice,
21-26 cells/group, 10 z-discs/cell. P-values were calculated via one-way ANOVA with
Tukey’s multiple comparison test.
Discussion
GSK-3β is a central kinase in multiple critical signaling pathways in the heart, and
recent evidence suggests it can localize to and interact with myofilament proteins in
vitro 14, 161. However, the ability of GSK-3β to localize in vivo has been largely
unexplored. Utilizing both mouse and human tissue, we found that 1) GSK-3β binds to

the myofilament 2) GSK-3β localizes to the cardiac z-discs 3) localization is driven by
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phosphorylation at Y216 and 4) GSK-3β phosphorylates z-disc proteins in vivo.
GSK-3β Binds to the Myofilament
It has been shown that treatment of skinned myocytes with active, recombinant
GSK-3β results in phosphorylation of several z-disc and m-band proteins, as well as
altered myofilament function14, 161. While these studies show that GSK-3β can interact
with the myofilament, they use large, non-physiological concentrations of GSK-3β, and
may not reflect interactions that can occur in vivo. We therefore utilized techniques to
identify if endogenous GSK-3β localizes to the myofilament. We showed in myofilament
enriched tissue and skinned myocyte preparations that GSK-3β binds to the
myofilament. While GSK-3β has been quantified in different subcellular fraction, such as
the nucleus167 and mitochondria186, we are the first to show that GSK-3β pulls down with
the myofilament fraction. This begs the question, what signaling occurs that directs
GSK-3β to the myofilament? In the case of the nucleus, GSK-3β contains a nuclear
localization sequence and it can also be imported into the nucleus via transport
proteins167, 168. While there has been no identified localization sequence that drives
GSK-3β’s mitochondrial localization, it appears that pathological stress, such as what
occurs post myocardial infarction induces a translocation to the mitochondria10, 171, 187. It
is believed that this translocation is protective, as GSK-3β inhibits the opening of the
mitochondrial permeability transition pore. We find myofilament GSK-3β in healthy
control mice, as well as in non-failing human cardiomyocytes, however from our work it
is unclear if GSK-3β’s localization to the myofilament is stress induced. In fact, it is likely
that myofilament GSK-3β is required for normal cardiomyocyte function. To our
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knowledge, there is not an identified amino acid sequence which directs proteins to the
myofilament. Instead, GSK-3β may be modified by a post-translational modification,
such as phosphorylation.

Indeed, we found that GSK-3β phosphorylated at Y216 has a strong myofilament
association- while antibodies for total GSK-3β, S9 GSK-3β, and pY216 GSK-3β all
localized to the myofilament in our immunofluorescence experiments, this localization
appeared to be influenced by phosphorylation. pS9 GSK-3β had a relatively weak
myofilament staining pattern compared to total and Y216 GSK-3β. It is important to take
into consideration that the total GSK-3β antibody binds to GSK-3β that is both
phosphorylated and unphosphorylated, and that it is unlikely that phosphorylation at S9
or Y216 is mutually exclusive. Therefore, if pY216 is vital for driving myofilament
localization, this myofilament localization appears strongest when using an antibody in
which we are essentially enriching for this phosphorylation site. However, we still see
this myofilament localization with the total and pS9 antibodies, because these are likely
also binding to some pY216 GSK-3β.
We are thus interested in endogenous modifiers of Y216 and the signaling
pathways involved in altering this phosphorylation. This site has been shown to be autophosphorylated during folding149, 188, but also targeted by tyrosine kinases Fyn, PYK2,
and MEK150-152, 189. However, this work has all been performed in vitro and in noncardiomyocytes, so it is unknown if these mechanisms occur in vivo in the heart and if
they play a role in directing GSK-3β towards or away from the myofilament. We have
shown that alkaline phosphatase can dephosphorylate the Y216 site, but these were in
vitro experiments, with large, non-physiological amounts of both GSK-3β and alkaline
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phosphatase, and we do not know if this interaction occurs physiologically. It should be
noted that alkaline phosphatase does not only target Y216 and is likely also modifying
other phosphorylation sites on GSK-3β, as well as other myofilament proteins once
added to the skinned myocytes. This large de-phosphorylation of myofilament proteins

may be altering the ability of recombinant GSK-3β to bind to the myofilament regardless
of Y216 phosphorylation.
Another factor to take into consideration is that phosphorylation at Y216, in
addition to pS9, has been shown to be important for GSK-3β’s kinase activity. While
phosphorylation at S9 blocks GSK-3β’s priming substrate binding pocket,
phosphorylation at Y216 is presumed to increase GSK-3β’s kinase activity, because the
Y216 residue is located in the kinase’s activation loop190. Phosphorylation at Y216 is
thought to cause a change in conformation that further opens the activation loop.
Therefore, it is important that any modification to the Y216 site take into consideration
its effects on kinase activity, which we did not assess in this study.
GSK-3β Localizes to the Cardiac Z-Disc
As it was shown that treatment of skinned myocytes with recombinant GSK-3β
results in phosphorylation of myofilament proteins and increased calcium sensitivity14,
the presumed mechanism is that GSK-3β alters calcium sensitivity through
phosphorylation of myofilament proteins. Calcium sensitivity is typically associated with
modifications to the thin filament, and we hypothesized that GSK-3β may interact with
thin filament proteins. However, we identified GSK-3β at the z-disc, not the thin filament,
via immunostaining. Therefore, is GSK-3β altering calcium sensitivity by targeting and
modifying the z-disc? Z-discs are structures that anchor both the thin filament and titin

and are important for mechano-transduction, as the transmit the force signal across
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adjacent cardiomyocytes while also receiving and transmitting force from the external
environment33. However, modification of calcium sensitivity via the z-disc is a relatively
underexplored area. It has been shown that acetylation of muscle-LIM protein (MLP) by
a histone acetyltransferase leads to increased calcium sensitivity, however the
mechanism is unknown191.
Additionally, we saw significant decreases in several z-disc proteins (Supervillin,
SPEG, and abLIM-1) in GSK-3β KO mice in the mass spectrometry analysis and a
general decrease in pSer/Thr phosphorylation in these mice via immunofluorescence.
None of these proteins are associated with changes in calcium sensitivity, however they
are likely relevant to myofilament function. Supervillin is a cytoskeletal protein that plays
a role in cross-linking actin to cell membranes, and it has been found to anchor to zdiscs183. Loss of function mutations in Supervillin cause myofibrillar disorganization
which lead to myofibrillar myopathy192. SPEG is a serine/threonine kinase that belongs
to the myosin light chain family. It localizes to z-discs185 and is important for junctional
membrane complexes. Cardiomyocyte specific deletion of SPEG leads to disruption of
t-tubule formation, depressed excitation-contraction coupling, and development of
cardiomyopathy193. Very little is known about abLIM-1 in the heart, but it has been
shown that it can localize to cardiac z-discs and interact with F-actin182. Importantly,
abLIM-1 was also identified as a target of GSK-3β in a previous study14. While none of
these proteins and the residues we identified via phospho-proteomics are known to
modulate myofilament function, their known interaction with myofilament proteins could
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implicate them in contractility. It is also possible that modifications to these proteins alter
protein-protein interactions in the z-disc and change its structure and function.
Interestingly, it was previously shown in two mouse models of arrhythmogenic
cardiomyopathy (ACM) that GSK-3β has a cytosolic localization in healthy control
animals and an intercalated disc localization in animals with ACM, implying that this
localization is pathological179. We see a strong intercalated disc localization with all
three GSK-3β antibodies used. It is possible that this represents differences in cell
preparation and antibodies used. This intercalated disc staining may also represent
non-specific binding. If GSK-3β can localize to both the z-disc and intercalated disc, it
may have multiple distinct effects on myofilament function. Intercalated discs are
junctions between adjacent cardiomyocytes and can act as modified z-discs and are
also important structures for signaling and mechanotransduction194. It is likely that GSK3β can play separate and distinct roles at the z-discs and intercalated discs, dependent
upon which substrates it is targeting.
Limitations
We utilized the ability of myofilament proteins to be enriched and separated from
cytosolic contents. Using this preparation, we could also reduce non-cardiomyocyte cell
types in the left ventricle, such as fibroblasts, immune cells, smooth muscle cells etc.,
which also express GSK-3β. We identified GSK-3β in the myofilament, soluble, and
whole tissue fractions. While we cannot compare between fractions quantitatively, there
was a robust GSK-3β signal from the myofilament enrichments. While we anticipate
that this myofilament preparation is not perfect, the amount of GSK-3β present in the

myofilament fraction (along with the confirmatory immunofluorescence and other
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experiments) leads us to believe that its presence is due to more than contamination.
We performed immunoprecipitation experiments in myofilament enriched tissue
in which we used GSK-3β antibodies as bait. While we were not able to pull down a
noticeable amount of myofilament proteins with the total GSK-3β and pS9 GSK-3β
antibodies, (despite showing via immunofluorescence that they bind to the
myofilament), the pY216 GSK-3β antibody pulled down what appeared to be the entire
myofilament fraction. While we do not presume that pY216 GSK-3β is binding to each of
the proteins visualized in the stained gel, we do believe this means it is binding strongly
enough to one or several myofilament proteins that it pulls the entire myofilament down
with it. However, it is important to point out that this could be due to non-specific binding
of the antibody (a reason we also created tagged adenoviruses to repeat the
coimmunoprecipitation experiments). We also pulled down myofilament proteins in the
NRVM experiments in which we pulled down with antibodies for the tag found in all
phospho-mutants in skinned cells.
In the context of the adenoviral overexpression of GSK-3β phospho-mutants in
NRVMs it should be noted that the mutation of a tyrosine to a glutamic acid is not a true
phospho-mimetic, as it lacks the aromatic ring of a tyrosine, but others have shown that
it can be used as a tyrosine phospho-mimetic195, 196. In addition, our experiments
provide evidence that the Y216 site is important for GSK-3β’s localization to the
myofilament, however it is unclear if phosphorylation at Y216 occurs in conjunction with
additional mechanisms to drive localization. Further evidence that Y216 may not be the

sole driver of GSK-3β myofilament localization is that we identify pY216 GSK-3β in
cytosolic fractions from both human and mice preparations.
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CHAPTER 4
GSK-3β MODULATES LENGTH-DEPENDENT ACTIVATION
Introduction
Changes in myofilament calcium sensitivity are frequently observed in heart
failure due to altered phosphorylation of thin filament proteins197. However, depending
on the specific heart failure etiology62, 63, 198, comorbidities199, and treatments200,
myofilament calcium de-sensitization and over-sensitization are both observed.
Unfortunately, both situations are detrimental, with de-sensitization resulting in hypocontractility and worsening of the weakened heart while over-sensitization can cause
arrhythmias and slowed relaxation63. In addition, calcium sensitivity is dynamically
regulated in response to acute changes, such as stretch. Length-dependent activation
(LDA) is the mechanism by which stretch increases calcium sensitivity in
cardiomyocytes and underlies the organ level Frank-Starling Law103, 110 that allows the
heart to respond to changes in blood volume on a beat-to-beat basis. Animal models of
heart failure exhibit a depressed Frank-Starling response106, 108, however in humans this
is less clear, as Frank-Starling/LDA has been found to be both diminished105, 201, 202 and
unaffected107, 109 by heart failure.
It was previously found that GSK-3β activity was depressed in a dog model of
heart failure concurrent with cardiac dyssynchrony14, which typically arises from
conduction abnormalities and results in premature activation of one region of the
62

ventricular

wall14.
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The observed decrease in GSK-3β activity correlated with depressed

myofilament calcium sensitivity, which could be rescued in vitro with exposure to
exogenous GSK-3β. Furthermore, GSK-3β was uncoupled from Akt, its canonical
upstream de-activator, suggesting an independently regulated pool of GSK-3β14.
However, there was no direct evidence that GSK-3β localizes to the myofilament or
regulates myofilament function in vivo. We showed in Chapter 3 that GSK-3β can
localize to the myofilament, specifically to the z-disc, where it phosphorylates z-disc
proteins. If GSK-3β is capable of modulating calcium sensitivity in vivo it is likely that
this occurs through the z-disc, as this is where it localizes and phosphorylates proteins.
An interesting, but highly unexplored mechanism of calcium sensitivity is though
modification of z-disc proteins. Z-discs are important for both structure, signaling, and
protein turnover203. Structurally they are the binding sites of actin (via α-actinin) and titin
(via telethonin), and therefore are important for transmitting force across adjacent
sarcomeres. In addition to anchoring the thin filament, α-actinin also cross-links
adjacent z-discs. During contraction the z-disc lattice undergoes conformational
changes itself, which is believed to be evidence that these structures are important for
stress-sensing and mechano-transduction204, 205. Z-discs also connect to the t-tubule
system and sarcoplasmic reticulum, linking them to calcium handling signaling206.
Additionally, z-discs have been found to be hotspots for autophagy and protein
turnover207. Therefore it is unsurprising that mutations to several z-disc proteins, such
as α-actinin, Muscle LIM protein (MLP), Telethonin, actin, Integrin-linked kinase (ILK),
Calsarcin 1, Cypher, Desmin, Bcl2-associated athanogene 3 (BAG3), and Titin are
found in high prevalence in cardiomyopathies208.
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An underexplored area is the ability of z-disc proteins to alter calcium sensitivity.
It was found that acetylation of the z-disc protein muscle LIM protein (MLP) causes

increased calcium sensitivity191. Additionally, treatment of skinned myocytes with S100,
a protein which localizes to the z-disc endogenously, causes decreased calcium
sensitivity209, 210. It is important to note that both MLP and S100 are considered to be zdisc proteins but can localize to other subcellular localizations. Therefore, it is possible
that these proteins sense changes in stress at the z-line and then translocate to the
nucleus to drive transcriptional changes. However, it seems unlikely that changes at the
timescale of transcription and translation are the mechanism of altering calcium
sensitivity, which is typically altered by fast and transient events like phosphorylation.
The objective of this study was to determine the role of GSK-3β in modulating
myofilament function in vivo. Previous in vitro work found that recombinant GSK-3β
treatment could sensitize cells from dogs with dyssynchronous heart failure14, however
it was unknown if GSK-3β can sensitize in vivo. We hypothesized that GSK-3β KO mice
would have reduced calcium sensitivity compared to littermate controls. Force-calcium
experiments were performed using skinned myocytes from CON and GSK-3β KO mice
at both short and long sarcomere lengths. These skinned myocytes were also used for
measuring passive tension. Recombinant GSK-3β treatments were performed on skin
myocytes to determine whether GSK-3β can also sensitize in vitro in this model.
Additionally, we explored one of GSK-3β’s z-disc phosphorylation targets, actin binding
LIM domain protein 1 (abLIM-1) in its ability to bind titin and modulate LDA. Our findings
indicate that GSK-3β is important for modulating length-dependent activation, or the
sensitization of the myofilament to calcium with stretch, and that this mechanism is likely

mediated through changes to titin passive tension properties. GSK-3β’s z-disc target
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abLIM-1 is a promising modulator of LDA, that should be explored further.
Methods
Mice
Cardiomyocyte-specific, conditional GSK-3βflox/flox, α-MHC Mer Cre Mer (MCM) +
mice9 (a kind gift from Dr. Thomas Force and rederived at Jackson Laboratories) and
littermate controls, GSK-3βflox/flox α-MHC MCM -, were generated from several crosses
of GSK-3βflox/flox and α-MHC Mer Cre Mer (MCM) strains, both on the C57BL/6J
background. Mice were backcrossed with wild type C57BL/6J mice every 10-12
generations. Cardiac Myosin Binding Protein-C (cMyBP-C) null mice, cMyBP-Ct/t211, 212
and Cardiomyocyte-specific cMyBP-CΔC0C1f, α-MHC mice81 were generated as
described and characterized previously. Approximately equal numbers of male and
female mice, age 12-14 weeks, were used in all experiments.
Skinned-Myocyte Experiments
Myocytes were prepared by homogenizing left ventricular tissue in isolation
solution (in mM: 5.5Na2ATP, 7.11 MgCl2, 2 EGTA, 108.01 KCL, 891 KOH, 10 imidazole,
10 DTT) with 0.3% Triton and protease and phosphatase inhibitors (Thermo Fisher
Scientific) and left on ice for twenty minutes. After “skinning”, the mixture was
centrifuged at 120xg, and the pellet was re-suspended twice in isolation solution without
triton to remove the detergent. A single myocyte was selected and attached to a force
transducer and a length controller (Aurora Scientific) via pins with UV-curing glue. The
sarcomere length was monitored using a video camera and calculated by the HighSpeed Video Sarcomere Length software (Aurora Scientific) and was kept constant at

the experimental SL (1.9, 2.1 or 2.3) throughout the experiment. The temperature was
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kept constant at 25°C. The myocyte was kept in relaxing solution (6.2 ATP, 6.5 MgCl2,
10 EGTA, 100 BES, 10 phosphocreatine, 47.6 KProp) with phosphatase and protease
inhibitors. The force was measured by moving the myocytes to different baths
containing different calcium concentrations ranging from 0 to saturating conditions,
created by mixing relaxing and activation solutions. The Activation solution contained (in
mM): 5.95 Na2ATP, 6.2 MgCl2, 10 Ca2+-EGTA, 100 BES, 10 phosphocreatine, 29.98
KProp, 10 DTT, phosphatase and protease inhibitors. Passive tension was measured in
cells in relax solution. The sarcomere length was increased from 1.6 to 2.6 μm, with
force measurements being taken every 0.2 μm. Each cell was then fit to an exponential
curve.
Data from skinned myocytes were statistically analyzed on a per cell basis, not
on a per animal basis. Approximately equal numbers of cells were analyzed from each
animal, although this may introduce bias from non-independence.
X-Ray Diffraction
Papillary muscles were dissected from mice and skinned at 1% Triton X in
relaxing solution (containing in mM: 6.3 Na2ATP, 6.48 MgCl2, 10 EGTA, 100 BES, 10
phosphocreatine, 49.76 Potassium propionate, 10 DTT, and creatine kinase 10 U/ml)
overnight. Next day, the muscles were washed with fresh cold relaxing solution and
muscles were further dissected in fiber strips, clipped on aluminum T-clips and stored in
cold relaxing solution for the day.
X-ray diffraction patterns were collected from freshly skinned muscle strips using
the small-angle instrument at BioCAT beamline 18ID at the Advanced Photon Source,
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Argonne National Laboratory. The X-ray beam was focused to ~0.04 × 0.10 mm at the

detector plane. The sample-to-detector distance was ~3.5 m, and the X-ray wavelength
was 0.103 nm. Isolated fiber bundles (~200 µm diameter, 2-3 mm long) were mounted
between a force transducer (Model 402A, Aurora Scientific) and a static hook. Force
was monitored using the Muscle Dynamic Control system (Model 610A, Aurora
Scientific). Sarcomere length was adjusted by laser diffraction using a 4-mW HeNe
laser. Diffraction patterns were collected at sarcomere lengths of 2.1 µm and 2.4 µm. Xray exposures were 1 s at an incident flux of ∼3×1012 photons per second, and the
patterns were collected on a CCD-based X-ray detector (Mar 165; Rayonix Inc.

Evanston, IL). The data were analyzed using data reduction programs belonging to the
MuscleX software package developed at BioCAT. The spacings of the 1,0 equatorial Xray reflections were measured using the “Equator” routine in the MuscleX software
package as described previously.
Titin Gels
Titin sample and gel preparation methods were adapted from established
protocols213. 15-20 mg pieces were obtained from each heart under liquid nitrogen.
Tissues were pulverized using Kontes Dounce homogenizers (Kimble Chase,
Rockwood, TN) while being maintained in liquid nitrogen. Tissues were solubilized at
60°C in the following buffer: 4M Urea, 1M Thiourea, 1.5% SDS, 25mM Tris-HCl,
37.5mM DTT, 25% Glycerol, + protease and phosphatase inhibitors (1:100) for 10
minutes. Solubilized tissue was then centrifuged at 14.8k rpm for 5 minutes and then
aliquoted. Protein concentrations were determined using an RC/D assay (BioRad).
Each sample was loaded in on a 1% agarose (SeaKem™ Gold, Lonza Group,

Switzerland) gel: 50mM Tris Base, 384mM Glycine, 0.1% SDS, 30% Glycerol, using a
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large-format gel system (Hoeffer SE600X, Hoefer, Inc., Holliston, MA). Gels were run at
15mA/gel for 200 minutes at 4°C and then stained with Coomassie. Gels were scanned
using an Azure C600 imager and quantified using Image J.
RNA Extraction and cDNA Synthesis
RNA was extracted from LV from GSK-3β CON and KO mice using an RNeasy
Fibrous Tissue Kit (Qiagen), following the manufacturer protocol. 5 µg RNA was
synthesized to cDNA using SuperScript IV Reverse Transcriptase (Thermofisher)
following the manufacturers protocol.
qPCR
SYBR Green PCR Master Mix (Applied Biosystems), 2 µl of cDNA, and 0.25 µM
of primers were used for each real-time qPCR reaction. Data was analyzed using the Δ
ΔΔCT method in which ABLIM-1 RNA expression was compared to that of beta actin.

ABLIM-1 primer Sequence:
F: CAC ATC AGG CTA TGA GGA CAA G
R: CGA TCC CGG ACA TCT TGA TAA C
Beta Actin Primer Sequence:
F: GAG GTA TCC TGA CCC TGA AGT A
R: CAC ACG CAG CTC ATT GTA GA

Coimmunoprecipitation
50 µl of Dynabeads Protein G (Thermo Fisher Scientific) were incubated with
either 10 µl GST antibody (Cell Signaling) or mouse IgG diluted into 200 µl of PBS-T for
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10 minutes at room temperature. Antibody conjugated beads were cross-linked with 20
mM dimethyl pimelimidate dihydrochloride in 100 mM sodium borate (pH 9).
Crosslinking was inactivated by washing twice with antibody blocking buffer (200 mM
ethanolamine pH 8). Crosslinked beads were then blocked at 4 degrees for two hours.
Beads were then washed three times with IAP Buffer (50 mM MOPS (pH 7.2), 10 mM
sodium phosphate, 50 mM NaCl). The beads were then incubated with recombinant
Z1Z2 and abLIM-1 diluted in PBS-T for 15 minutes at room temperature. Treatment

groups were as follows: IgG= 0.24 µg of Z1Z2 (a kind gift from Siegfried Labeit) and 0.5
µg of GST-tagged abLIM-1 (Novus Biologicals, H00003983-P01), BL= 0.24 µg of Z1Z2
and 0.5 µg of GST-tagged abLIM-1, GSK = 0.24 µg of Z1Z2 and 0.5 µg of GST-tagged
abLIM-1 that had been pre-treated with 0.5 µg of recombinant GSK-3β for 10 minutes).
The beads were then gently washed 6 times with PBS-T. After the final wash, the beads
were eluted in 0.15% Formic acid. Samples were treated with 5 mM DTT, followed by
10 mM Iodoacetamide, and then digested with 0.02 ug of trypsin overnight. Samples
were run through C18 spin columns (Thermo Fisher) and then dried in a speed vacuum.
Samples were then reconstituted in HPLC water with 0.15% formic acid and run on an
Ultimate 3000 nHPLC coupled to an Orbitrap XL Mass Spectrometer (Thermo Scientific)
using a 250mm EASY-Spray LC column. Data were analyzed on PEAKs software, and
spectra were searched against a custom Z1Z2 and abLIM-1 database.
siRNA
abLIM-1 siRNA (Sigma-Aldrich, SASI,Rn02_00205714) or scrambled control
RNA (Sigma Aldrich) was transfected into iPSC cells with Lipofectamine RNAiMAX
Reagent (Thermofisher) following manufacturer’s instructions. Briefly, Lipofectramine
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was diluted into Opti-MEM, and then combined with diluted siRNA (10 uM). After a 10-

minute incubation at room temperature, the siRNA-lipid complex was added to the cells.
After two hours, the media was replaced with standard maintenance media. Cells were
harvested or used for experiments after 72 hours.
Engineered Heart Tissue
To prepare decellularized porcine scaffolds, fresh pig hearts (Latella Farm, West
Haven, CT) were preserved in ice-cold DPBS with 5% pen-strep. Left ventricular free
wall portion of the hearts was trimmed and frozen on dry ice before cryostat sectioning
(Leica CM3050 S) into 150-µm slices. 2.5 mm × 6 mm scaffolds were laser-cut from the
slices, affixed to laser-cut PTFE holders, lysed (10mM Tris and 0.1% 0.5M EDTA in DI
water), decellularized (0.5% wt/vol sodium dodecyl sulfate in DPBS), and incubated
overnight before seeding (10% FBS and 2% pen-strep in DMEM).
For seeding, one million cells of iPSC-CMs (derived from a healthy control line
GM23338, Coriell Institute) and human adult cardiac fibroblasts (PromoCell 306-05A)
were seeded per EHT at a 9:1 ratio. Both cell types were dissociated with TrypLE and
resuspended in seeding media (10% FBS, 1% pen-strep, 1% NEAA, 1% L-glutamine,
and 1% sodium pyruvate in DMEM). Tissues were maintained in DMEM supplemented
with B27 with insulin and media were changed every other day.
A custom mechanical testing setup composed of a force transducer and linear
actuators was used to characterize the EHT biomechanical properties. EHTs were
maintained in Tyrode’s solution at physiological conditions during testing (1 Hz pacing,
35°C, and continuous perfusion). MATLAB scripts were used to record and process the
mechanical data.
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Statistics
Variables are expressed as mean ± standard error. Statistical significance was
calculated in GraphPad Prism (version 9) by t-test, one-way analysis of variance, or

two-way analysis of variance followed by the Tukey or Mann-Whitney post-hoc tests, as
indicated. Normality (by Shapiro Wilk test) and equal variance (by F-test for t-tests or
Brown-Forsythe test for ANOVAs) were tested prior to all parametric tests. P-values
less than 0.05 were considered statistically significant.
Results
GSK-3β KO Does Not Lead to Changes in Systolic Function
We utilized a cardiomyocyte-specific inducible GSK-3β knockout mouse
(GSK-3β flox/flox α-MHC MCM +) for all functional studies using skinned cardiomyocytes.
We first wanted to determine if this acute knockout of GSK-3β resulted in changes to
global heart function. This was determined by echocardiography. At 12 weeks of age
(used for all studies), there were no in vivo functional or structural differences between
CON and KO mice (Table 4), except a mild hypertrophy in the anterior wall, consistent
with GSK-3β’s role as an inhibitor of hypertrophy. It should be noted that these results
were collected from a separate cohort of animals than were used in Table 3, and some
of these values differ.
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Table 4. Effect of GSK-3β KO on Left Ventricular Systolic Function. n=12
mice/group. P-values calculated by unpaired t-test, * indicates p-values calculated
by unpaired non-parametric Mann-Whitney tests; Abbreviations: HR= heart rate,
BPM= beats per minute, LVAW;d= left ventricular anterior wall; diastole, LVAW;s=
left ventricular anterior wall; systole, LVID;d= left ventricular internal diameter;
diastole,, LVID;s= left ventricular internal diameter; systole, LVPW;d=left ventricular
posterior wall; diastole, LVPW;s= left ventricular posterior wall;systole, EF=ejection
Parameter

Control

KO

p-value

Weight (g)

20.76 ± 2.10

19.40 ± 3.29

0.20

HR (BPM)

376.67 ± 72.30

355.88 ± 31.24

0.48

LVAW;d (mm)

0.73 ± 0.10

0.84 ± 0.18

0.087

LVAW;s (mm)

1.0 ± 0.14

1.18 ± 0.23

0.036

LVID;d (mm)

3.87 ± 0.50

3.87 ± 0.49

0.99

LVID;s (mm)

2.84 ± 0.55

2.78 ± 0.52

0.77

LVPW;d (mm)

0.90 ± 0.39

0.87 ± 0.33

0.99*

LVPW;s (mm)

1.17 ± 0.42

1.19 ± 0.51

0.99*

113.84 ± 27.88

123.82 ± 38.93

0.48

LV Vol;d (µl)

66.04 ± 18.8

66.02 ± 18.49

0.99

LV Vol;s (µl)

32.54 ± 13.78

30.58 ± 11.63

0.71

EF (%)

52.42 ± 11.30

54.52 ± 12.52

0.67

FS (%)

26.84 ± 7.20

28.37 ± 8,50

0.64

LV Mass AW (mg)

GSK-3β Modulates Length-Dependent Activation in Vivo
GSK-3β was previously found to be altered in a model of cardiac dyssynchrony,
which is believed to cause impaired mechano-transduction14. Additionally, GSK-3β was
found to localize to the z-disc and phosphorylate z-disc targets. The z-discs have more
recently been appreciated as signaling hubs, and critical for mechano-transduction, as

z-discs transmit force to adjacent

sarcomeres33.

We therefore were interested in if
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mechano-transduction was altered in the GSK-3β KO mice. An established mechanotransduction pathway in cardiomyocytes is called length-dependent activation (LDA).
LDA occurs when a cardiomyocyte is stretched, or sarcomere length is increased,
resulting in increased force of contraction, via enhanced calcium sensitivity. We
therefore performed LDA experiments on skinned myocytes from CON and KO mice.
In these experiments, we permeabilized the cells in order to wash away cytosolic
contents and directly expose the myofilament to calcium, which will elicit a contraction.
Skinned cells were pinned to a force transducer, which allowed us to measure the
strength of the contraction, and a length controller, which allowed us to set the
sarcomere length. Cells were exposed to increasing amounts of calcium until a
saturating effect was reached. There experiments allow us to calculate the maximal
force of contraction as well as the EC50, a measurement of calcium sensitivity. LDA
experiments were performed by first generating a force-calcium curve at a “short” SL of
1.9 µm. The cell was then stretched to a “long” SL of 2.3 µm and another curve was
measured (n=4-5 mice/group, 2-4 cells/mouse). Stretching CON myocytes increased
both Fmax and calcium sensitivity (p=6.4x10-4, p=4.97x10-4 respectively, via two-way
repeated measures ANOVA, Figure 13A-D), the expected effect of LDA. Conversely,
myocytes from GSK-3β KO mice exhibited no significant change in either Fmax or EC50
with stretch. Additionally, there was no statistical difference in calcium sensitivity
between the two groups at the short SL (p=0.33).
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Figure 13. Genetic Ablation of GSK-3β Results in Loss of Length-Dependent
Activation. (A) Mean force as a function of calcium concentration and fitted curves for
skinned myocytes from CON and (B) KO mice in which curves were measured at a
sarcomere length (SL) of 1.9 µm and then 2.3 µm. Normalized curves are shown in the
bottom right of each graph to emphasize shifts in calcium sensitivity. (C) Delta Fmax and
(D) EC50 for CON and GSK-3β KO mice between SL 1.9 and 2.3 µm (p=0.0084 by
unpaired T-test, n=12 myocytes from 4 CON and 3 KO mice). (E) Summary data of
EC50 of CON and KO mice at baseline (BL) and after GSK-3β treatment (GSK-3β)
depicted as mean± SEM at a short SL of 1.9 μm. CON (n= 8 myocytes from 3 mice) and
KO (n= 8 myocytes from 3 mice). P-values were calculated by repeated measures twoway ANOVA. (F) The same experiments were performed on a separate cohort of
animals at a long SL of 2.2 μm in CON (n = 11 myocytes from 4 mice) and KO (n = 7
myocytes from 3 mice). P-values were calculated by repeated measures two-way
ANOVA.
To ensure this was a direct effect of GSK-3β, we next tested whether exogenous
GSK-3β would similarly enhance calcium sensitivity at long sarcomere lengths while
having no impact at short sarcomere lengths. To avoid potential rundown from four

subsequent activations, we performed paired pre- and post-GSK-3β treatments
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separately at short and long sarcomere lengths in CON and KO mice. Exogenous GSK3β treatment (0.1 μg for 15 minutes) had no effect in myocytes at a short sarcomere
length (n= 8 cells from 3 mice/group), but increased calcium sensitivity when the
myocytes were stretched to a long sarcomere length (n= 11 myocytes from 4 mice;
effect of treatment p=0.046) (Figure 14A-D). However, this increase was very modest.
Interestingly, when analyzed by two-way ANOVA, there was no interaction between
genotype and treatment. This result indicates exogenous GSK-3β can enhance LDA in
both CON and KO myocytes and suggests the functional impact of GSK-3β is not
saturated in normal hearts.
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Figure 14. Recombinant GSK-3β Can Only Sensitize at Long Sarcomere
Lengths. (A) Summary data of EC50 of CON and KO mice at baseline (BL) and after
GSK-3β treatment (GSK-3β) depicted as mean± SEM at a short SL of 1.9 μm. CON
(n= 8 myocytes from 3 mice) and KO (n= 8 myocytes from 3 mice). P-values were
calculated by repeated measures two-way ANOVA. (B) The same experiments were
performed on a separate cohort of animals at a long SL of 2.2 μm in Con (n = 11
myocytes from 4 mice) and KO (n = 7 myocytes from 3 mice). P-values were
calculated by repeated measures two-way ANOVA. Effect of paired treatments on
EC50 at short (C) and long (D) sarcomere lengths. CON (blue) and GSK3b KO
(green) mice have been combined. Statistics were calculated by paired t-test.

Exogenous GSK-3β Cannot Rescue Function in the Absence of cMyBP-C
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We next determined whether genetic removal of a protein in the LDA pathway,
specifically, cardiac myosin binding protein-C (cMyBP-C), would block the ability of
exogenous GSK-3β to rescue calcium sensitivity at a long SL. cMyBP-C is a thick
filament protein with domains in its N-terminus which interact with both the thick and the
thin filament79 while its C-terminus binds titin214. Its interaction with myosin has been
shown to act as a brake on cross-bridge formation, and its interaction with the thin
filament has been shown to increase calcium sensitivity215. cMyBP-C has also been
studied in the context of LDA: knockout of cMyBP-C results in reduced LDA216, while
phosphorylation of several of its residues in its M-domain result in enhanced LDA82.
We used two genetically engineered mouse lines, one with complete ablation of
cMyBP-C (cMyBP-C KO)212 and one transgenic expressing a truncated cMyBP-C
lacking the N-terminal C0 and C1 domains that interact with the thin filament (ΔC0C1f)81. Both strains have been previously studied, although we confirmed their cMyBPC expression profiles here (Figure 15A). We measured force-calcium relationships
before and after exogenous GSK-3β treatment (n=3 mice/group, 3 cells/mouse), all at
sarcomere lengths of 2.2 μm. While GSK-3β increased calcium sensitivity at long SLs in
CON myocytes, it failed to affect calcium sensitivity in the cMyBP-C KO or cMyBPCΔC0C1f mice (Figure 15B-G). This indicates that GSK-3β cannot sensitize the
myofilament when cMyBP-C is absent, making it likely that its effect on LDA is upstream
of cMyBP-C (Figure 15H)
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Figure 15. GSK-3β is Unable to Modulate Calcium Sensitivity in cMyBP-C KO or
cMyBP-CΔC0-C1f Mice. (A) Representative western blot analyses demonstrating the level
of cMyBP-C in cMyBP-C KO and cMyBP-CΔC0-C1f mouse hearts, compared to control
mouse hearts. The upper panel was performed with both amino terminal-specific cMyBPC and actin antibodies. The bottom panel was treated with carboxy terminal-specific
cMyBP-C antibodies. (B) Mean force as a function of calcium concentration and fitted
curves for skinned myocytes at baseline and with exogenous GSK-3β treatment from LV
from Control (n= 3 mice, 2-3 cells/mouse), (C) MyBP-C KO (n= 3 mice, 3 cells/ mouse)
and (D) MyBP-CΔC0C1f (n= 3 mice, 2 cells/mouse) mice. The SL was set to 2.1 μm for all
experiments. Summary data of (E) ΔEC50 Mean ± SEM: Control: -0.237 ± 0.080, cMyBPC KO: 0.137 ± 0.064, MyBP-CΔC0C1f: 0.042 ± 0.045 (F) ΔFmax Mean ± SEM: Control:
1.939 ± 1.26, cMyBP-C KO: 0.78 ± 0.77, MyBP-CΔC0C1f: 0.198 ± 0.609 and (G) ΔHill
slope Mean ± SEM: Control: -0.901 ± 0.419, cMyBP-C KO: -0.128 ± 0.405, cMyBPCΔC0C1f: 0.321 ± 0.057 . Statistics were calculated by one-way ANOVA. (H) Proposed
mechanism of recombinant GSK-3β’s on LDA pathway involving cMyBP-C being a
downstream effector.
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TnI and cMyBP-C Phosphorylation and Lattice Spacing Are Unchanged in the
GSK-3β KO Mice
We next sought to explore the mechanism of GSK-3β’s impact on LDA.
Phosphorylation of cardiac troponin I (TnI) at S23/24 and cMyBP-C at S273/S282/S302
both enhance LDA82. We therefore quantified phosphorylation of both proteins using
western blot to determine if reduced phosphorylation of both or either of these proteins
was contributing to the reduced LDA in the GSK-3β KO mice (Figure 16A-D). However,
none of these sites were significantly altered (n=4).

Figure 16. Troponin I and cMyBP-C Phosphorylation Are Unchanged in GSK-3β
KO Mice. (A) Western blot depicting total Troponin I (TnI) and pS23/24 TnI in Control
and GSK-3β KO mice. Phosphorylation sites on cMyBP-C in Control and GSK-3β KO
mice (B) pS273, (C) pS282, and (D) pS302 normalized to total cMyBP-C (n=4/group).
Groups were compared with Mann-Whitney tests.

When the sarcomere is stretched, interfilament lattice spacing, or the distance
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between the thick and thin filaments, decreases, promoting force generation as the
probability of cross-bridge formation occurring increases114. We performed forcecalcium experiments in which we incubated skinned myocytes with 3% Dextran, which
physically compresses the lattice and decreases interfilament spacing. Multiple groups
have shown that compressing the lattice with dextran increases calcium sensitivity113,
115, 116.

We performed baseline force-calcium curves in myocytes from CON and KO

mice at a SL of 2.1, and then incubated cells with 3% Dextran for 20 minutes before
performing another force-calcium curve (n=10-11 cells from 3 mice). Calcium sensitivity
increased in both groups, and there were no significant differences (Figure 17A-C).
Additionally, we utilized synchrotron small angle x-ray diffraction to approximate
interfilament lattice spacing in skinned papillary muscles. Measurements were taking in
a relax solution at both short (2.1 μm) and long (2.4 μm) SLs (CON n=16 fibers from 6
animals; KO n= 11 fibers from 4 animals). Lattice spacing significantly decreased with
stretch, but there were no statistical differences between GSK-3β CON and KO fibers
(Figure 17D).
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Figure 17. GSK-3β KO Mice Have Normal Lattice Spacing. (A) Mean force as a
function of calcium concentration and fitted curves for skinned myocytes from CON and
(B) KO mice at BL and after incubation with 3% Dextran. All curves were measured at a
SL of 2.1 μm (C) Summary data of delta EC50 in CON and KO mice (n= 10-11 cells
from 3 mice; p=0.2068 by unpaired t-test). (D) Summary d10 (lattice spacing) collected
by x-ray diffraction data from skinned papillary muscle fibers from CON (16 fibers from
6 animals) and GSK-3β KO mice (11 fibers from 4 animals). Fibers were measured at
SL 2.1 and 2.4 µm. (effect of SL p=4.0 x 10-6 by repeated measures 2-way ANOVA with
Sidak’s multiple pair-wise comparison test).
GSK-3β is Required for Maintaining Passive Tension
As the molecular spring responsible for passive tension and resting sarcomere
length, titin acts as a “stretch sensor” for LDA. For example, transgenic expression of a
more compliant titin isoform depressed LDA98. To assess whether titin may be
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contributing to GSK-3β’s modulation of LDA, we assessed passive tension in CON and
KO myocytes. Myocytes were skinned and glued to pins following the same procedure
as the preparation for fore-calcium experiments. Myocytes from KO mice had
significantly decreased passive tension at long SLs (2.4 and 2.6 μm, p=0.0083 and
p=0.016 by unpaired t-test, n=4 mice/group, 3-4 cells/mouse, Figure 18A). If GSK-3β
indeed modulates LDA via passive tension, recombinant GSK-3β should be able to
increase passive tension similar to its effect on calcium sensitivity at long sarcomere
lengths. Therefore, we also performed passive tension experiments in CON and GSK-

3β KO myocytes before and after treatment with exogenous GSK-3β (0.1 μg GSK-3β for
5 minutes). GSK-3β treatment significantly increased passive tension in both CON and
KO myocytes (calculated by paired t-test, n= 3 mice/group, 4-5 cells/mouse, Figure
18B-C).
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Figure 18. GSK-3β KO Mice Have Increased Titin Compliance. (A) Passive tension
measured in CON and GSK-3β KO mice at SLs from 1.6 to 2.6 µm. (p-values
determined by unpaired parametric t-test, with the exception of data collected at 2.0,
which was determined by unpaired non-parametric Mann-Whitney T-test). Passive
tension measured in (B) CON (n=3 mice/4-5 cells per mouse; p-values: 1.8=0.88W,
2.0=0.022W, 2.2=0.060P, 2.4=0.011W, 2.6=0.15P) and (C) KO mice (n=3 mice/4-5 cells
per mouse; p-values: 1.8=0.69W, 2.0=0.080W, 2.2=0.20P, 2.4=0.043P, 2.6=0.0073P) at
baseline and with GSK-3β treatment. P-values were determined by paired t-test,
pParametric test, WNon-parametric Wilcoxon Test.

Due to its elastic domains, titin acts as a length sensor, setting the resting
sarcomere length86. We skinned myocytes from CON and KO mice and performed
immunostaining with ⍺-actinin, a z-disc protein. We then utilized the fast fourier

transform (FFT) function in ImageJ to measure (resting) sarcomere lengths in these
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cells. Resting sarcomere length was increased in GSK-3β KO myocytes compared to
CON myocytes (n=3 mice/group, 30 cells/mouse, p=0.013 by t-test, Figure 19A-B).
Together, these results indicate that loss of GSK-3β from the myofilament results in a
more compliant titin, which is known to depress LDA.

Figure 19. GSK-3β KO Mice Have Increased Resting Sarcomere Length.
(A) Representative images of fixed tissue from CON and KO mice in which the z-disc
is designated with α-actinin (n=30 cells/animal from 3 animals/group). Scale bar = 10
µm. (B) Summary data of resting SL (µm) (p=0.013 by non-parametric Mann-Whitney
t-test) shown as means ± SEM.

There are two isoforms of titin, the stiff N2B and more compliant N2BA86, and it is
possible the observed change in passive tension was due to a switch in the relative
expression of these two isoforms. We therefore ran titin gels in order to separate and
quantify N2B and N2BA in CON and KO mice. We found the isoform composition to be
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unchanged (n=5-6/group, Figure 20). Thus, the decrease in passive tension in KO cells
was likely due to reduced phosphorylation of GSK-3β’s myofilament targets.

Figure 20. The Decrease in Passive Tension in GSK-3β KO Mice is Not Due to
Titin Isoform Switching. Representative Coomassie stained gel with quantification
below of CON and GSK-3β KO mice in which titin isoforms N2BA, N2B, degraded titin
(T2), and myosin are indicated by arrows (n= 5-6 mice/group). P-value was determined
by Mann-Whitney test.
abLIM-1 Interacts with Titin at the Z-Disc and is Required for Normal LDA
Of the GSK-3β phospho-targets we identified by mass spectrometry, abLIM-1
was of specific interest as multiple phosphorylation sites on the protein were decreased
in the KO mice, indicating strong regulation by GSK-3β (Figure 21).
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Figure 21. GSK-3β Phosphorylates the Disordered Region of abLIM-1. Graphic of
abLIM-1 domains and phosphorylation sites. Sites depicted in black are unchanged in
GSK-3β KO mice, and sites depicted in red were reduced.

We first characterized abLIM-1 protein and transcript expression in the KO mice.
There were no statistical differences in abLIM-1 transcript (n=4) levels (Figure 22A) or
whole tissue abLIM-1 protein levels were detected (n=5) in the KO mice (Figure 22B).
To determine if abLIM-1 localization was altered in the KO mice, we performed
immunofluorescence experiments on skinned myocytes from CON and KO mice,
probing for ⍺-actinin and abLIM-1. Immunofluorescence in CON and KO myocytes

showed abLIM-1 localizes to the z-disc (Figure 22DC) as previously found182 and is
solely a sarcomeric protein, as abLIM-1 was only detected in the myofilament fraction
and absent from the soluble, primarily cytosolic, fraction (n= 3 CON, 4 KO) (Figure
22E).
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Figure 22. abLIM-1 Localizes to the Z-Disc. (A) RNA transcript levels of abLIM-1 in
GSK-3β KO mice (n=4). Statistics were calculated by Mann-Whitney test. (B)
Representative western blot of abLIM-1 in whole tissue lysis of CON and GSK-3β KO
mice. (C) abLIM-1 normalized to total protein in CON and KO mice (n=5). Statistics
were calculated via non-parametric Mann-Whitney test (D) abLIM-1 (green) and αactinin (pink) staining in CON and GSK-3β KO mouse LV. (E) abLIM-1 and total
protein in myofilament and soluble fractions

The N-terminus of titin, specifically the Z1Z2 domains and z-repeats, localizes to
the z-disc. The Z1Z2 domains bind to telethonin (T-CAP), a complex that is important
for stress-sensing at the z-disc and involved in maintaining passive tension. As passive
tension was decreased in the GSK-3β KO mice, we hypothesized abLIM-1 interacts with
the Z1Z2 domains of titin at the z-disc. We performed co-immunoprecipitation
experiments in which we incubated recombinant GST-tagged abLIM-1 with Z1Z2

peptides (a kind gift from Dr. Siegfried Labeit). Using the GST-tag on abLIM-1 as bait,
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we were able to identify Z1Z2 in the elutants via mass spectrometry (Figure 23),
indicating that abLIM-1 can bind the Z1Z2 domains on titin. To determine whether this
interaction can be regulated by GSK-3β, we pre-treated abLIM-1 with GSK-3β and
found this ablated its interaction with Z1Z2 (n=4-5 samples/group; p=0.018 by ANOVA).

Figure 23. abLIM-1 Binds the Z1Z2 Domains of Titin. Quantification (area under
the curve) of Z1Z2 titin peptides non-specifically bound (IgG control) and pulled down
by GST-tagged abLIM-1, at baseline (BL) and with GSK-3β pre-treatment (GSK-3β)
obtained by mass spectrometry. n =1 with the following technical replicates: IgG=5,
BL=4, GSK-3β =5. P-values were calculated via one-way ANOVA and Tukey’s
multiple comparison test.
We next sought to determine mechanistically whether abLIM-1 is involved in LDA
signaling in the myocyte. We generated engineered human heart tissues (EHT) by
seeding de-cellularized myocardium with human induced pluripotent stem cell
cardiomyocytes (hiPSC-CMs) and allowed them to mature for two weeks. The EHTs
were then treated with either scrambled siRNA or abLIM-1 siRNA, which resulted in a
30% knockdown of abLIM-1 (p=0.018, Figure 24A-B). The abLIM-1 treatment did not
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result in alteration of cross-sectional area (CSA) of the EHTs (Figure 24C). EHTs were
paced at 1 Hz in Tyrodes solution while simultaneously measuring isometric twitch
force. To measure LDA, the EHT was slacked to -10% of the tissue culture length and
then stretched to +10%, all while continuing 1 Hz pacing (n = 6 scrambled, 7 abLIM-1).
While there was no statistical difference in peak twitch force at 10% stretch (Figure 24

D), there were differences in LDA when peak twitch force was normalized to 0% stretch
for each EHT. Both scrambled and abLIM-1 siRNA treated EHTs exhibited increased
twitch force with stretch, however the EHTs with reduced abLIM-1 showed enhanced
length sensitivity compared with the scrambled group, with a divergence occurring
around 2% stretch (Figure 24E). The greatest difference in force occurred at 10%
stretch (p=0.0043). These experiments indicate that abLIM-1 binds titin at the z-disc to
depress LDA, and that its phosphorylation by GSK-3β relieves this inhibition and results
in normal function.
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Figure 24. abLIM-1 Modulates Length-Dependent Activation. (A) Representative
western blot of abLIM-1 and total protein stain in scrambled and abLIM-1 EHTS (B)
Quantification of abLIM-1/total protein, normalized to scrambled (n=5, p=0.018). P-value
was calculated by Mann-Whitney test. (C) Cross-sectional area of scrambled and abLIM-1
EHTs at 10% stretch (n= 6-7, p= 0.0043). P-value was calculated via unpaired nonparametric Mann-Whitney t-test (D) Peak twitch forces at 10% stretch normalized to CSA.
(E) Twitch forces were measured at 72 steps between a -10% (of total EHT length) slack
to +10% stretch. Twitch forces are normalized to 0% stretch. (n values: Scrambled =6,
abLIM-1= 7). p =0.004 refers to the difference between groups at 10% stretch, calculated
by unpaired t-test

Discussion
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Recent evidence14, 161 suggests that GSK-3β regulates sarcomere contractile
function, although a direct mechanistic connection is lacking. To address this gap we
utilized an inducible cardiomyocyte-specific GSK-3β KO mouse model. We discovered
GSK-3β is essential for normal length-dependent activation, LDA, the ability of the
myocyte to respond to stretch, resulting in calcium desensitization at longer sarcomere
lengths. Mechanistically, this is via decreased titin-based passive tension observed in
the KO mice, which is a critical “length sensor” for LDA. GSK-3β phosphorylates several
z-disc proteins, including actin binding LIM protein 1 (abLIM-1). Almost nothing is known
about abLIM-1 in the heart, but we have found that it localizes to the z-disc where it can
bind to the Z1Z2 domains of titin, and this binding is blocked by GSK-3β
phosphorylation of abLIM-1. Furthermore, abLIM-1 acts as an inhibitor of LDA.
GSK-3β KO Results in Dampened Myofilament but Not Global Heart Function
Other groups have utilized constitutive knockouts, which led to the discovery that
GSK-3β is vital for embryonic heart development6. The cardiomyocyte-specific GSK-3β
KO mouse we have used in our studies has also been studied in the context of the
remodeling heart, where knockout was induced post-injury (MI and TAC) 9. We have
been the first to investigate the impact of cardiomyocyte-specific GSK-3β knockout on
baseline cardiovascular and myofilament function in adult animals. We limited the
knockout period to three weeks (one week on tamoxifen and two weeks to allow the
knockout to proceed), because this time frame gave us a robust knockout (70%) and we
saw minimal effects of the chronic Wnt signaling we would expect from the knockout of
cytosolic GSK-3β. Even with a two-week knockout we detected a small but significantly

increased thickness of the anterior left ventricular wall. Despite this, we found that

92

systolic function (determined by ejection fraction and fractional shortening calculation)
did not differ between CON and GSK-3β KO mice. It is possible that a chronic knockout
of GSK-3β may result in altered global heart function.
Despite normal global heart function we found that GSK-3β KO mice have
depressed LDA, the cellular mechanism behind the Frank-Starling law of the heart,
which states that the stroke volume of the LV increases as LV end diastolic volume
increases217, allowing the heart to respond to changes in volume on a beat-to-beat
basis. This behavior stems from the response of cardiomyocytes to stretch, which
results in an increase in force production, termed length-dependent activation (LDA).
LDA, and thus the Frank-Starling mechanism, can become depressed in heart failure105,
107, 109, 201, 202.

While most studies are conducted in patients with end stage heart failure,

animal models have shown that this mechanism may be lost in the earlier stages, prior
to hypertrophy and fibrosis106.
Despite the fact it was initially discovered over a century ago – the molecular
mechanisms of LDA are still unclear. There are several hypotheses of factors that
contribute to altered LDA supported by the existing work, and these may not be
exclusive, since such a critical behavior could warrant redundant pathways to operate.
There are currently three primary mechanisms for explaining LDA: 1) decreased interfilament spacing from sarcomeric stretch brings myosin heads closer to actin to
increase the likelihood of crossbridge formation, 2) phosphorylation/regulation of thin
filament proteins with stretch increases calcium sensitivity, and 3) stretch is sensed by
titin strain, resulting in structural rearrangement that favors crossbridge formation110. We

were able to rule out the first two mechanisms by which GSK-3β regulates LDA, as
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lattice spacing was not altered in GSK-3β KO mice and phospho-proteomics did not
identify any phosphorylation sites connected to LDA or calcium sensitivity82. Instead, our
data implicate a titin-based mechanism.
GSK-3β Modulates LDA via Titin
While it was initially believed that titin was only relevant in passive force
generation, work in recent years has identified it as a component of active contraction
as well98, 100, 118, 218, 219. Small-angle x-ray diffraction studies have shown that stretch
induces structural rearrangements of myosin and troponin98. Interestingly, this structural
rearrangement of troponin is different from that which occurs with calcium binding and
does not influence the affinity of TnC for calcium. In myocytes expressing a longer,
more compliant titin, this structural rearrangement fails to occur with stretch, and cells
do not have an LDA response when stretched to the same sarcomere lengths as cells
expressing wild type titin. However, these titin mutants do eventually exhibit LDA when
stretched to much longer sarcomere lengths, allowing the authors to conclude that titin
strain is important for the development of LDA. Our GSK-3β KO mice had decreased
passive tension at increased sarcomere lengths, which could be rescued by incubation
with recombinant GSK-3β. We hypothesize that this increased compliance of titin is
affecting the rearrangement of thick and thin filament proteins which occurs with stretch,
however we did not perform these same experiments on muscle fibers from our GSK-3β
KO mice. It should also be noted that we did not attempt to activate GSK-3β KO mice
cells at sarcomere lengths greater than 2.3 μm, but this experiment would give insight
into if LDA can be achieved.

It is interesting that recombinant GSK-3β could enhance passive tension, but
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only had a modest effect on increasing calcium sensitivity. One explanation for this is
that the mechanism of action by which GSK-3β increases the passive tension of titin is
intact in skinned cardiomyocytes, but the mechanism that occurs between increasing
passive tension and LDA is impaired due to the skinned and washed nature of the cells.
abLIM-1 is a Promising Downstream Regulator of GSK-3β
Mechano-transduction is vital to a healthy and functioning heart, as
cardiomyocytes continuously generate force through contraction, but are also exposed
to external forces such as hemodynamic load. Therefore, it is imperative that
cardiomyocytes are able to appropriately respond to mechanical changes by modifying
signaling pathways which lead to changes in structure and function. The z-discs have
been identified as important sites for stress-sensing, as they must respond to both
internal and external forces33, 220, 221. We chose to focus on the cardiac z-discs as sites
of altered mechano-transduction in our GSK-3β KO mice for several reasons. First, we
previously identified that GSK-3β localizes to the z-disc and phosphorylates several zdisc targets. Second, we found that passive tension, a property of titin, was decreased
in the GSK-3β KO mice, and titin itself anchors to the z-disc. While a great deal remains
unknown about titin’s structure, function, and interacting partners at the z-disc, there are
studies that support the hypothesis that altering titin’s interaction with z-disc proteins
can alter passive tension. For example, the Z1Z2 domains of titin, which are located in
its z-disc region, are highly compliant in isolation, but are stabilized via z-disc binding
partners222, 223. We therefore returned to our phospho-proteomics screen to identify

targets of GSK-3β that could interact with titin and be important for mechano-
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transduction.
Of the GSK-3β phosphorylated proteins identified in our phospho-proteomics
screen, we were most interested in abLIM-1. abLIM-1 has been the focus of very few
studies, only one of which identified it in the heart182. However, several proteins of the
same family, which contain LIM domains, such as Muscle LIM protein (MLP) and Four
and a half LIM domain protein (FHL1 and FHL2) have been shown to be stress/strain
sensors. Indeed, this work establishes abLIM-1 as a critical z-disc protein in maintaining
normal function. First, abLIM-1 interacts with the Z1Z2 domains of titin in vitro which
also interact with telethonin (T-CAP), an interaction important for stress-sensing,
maintaining passive tension223, 224, and likely LDA although this has not yet been shown.
Similar to T-CAP, abLIM-1 is also required for normal stress sensing at the zdisc, as siRNA-induced reduction in abLIM-1 significantly increased LDA. The direction
of this impact was somewhat surprising, as we anticipated facilitation or enhancement
of LDA by abLIM-1, and that its reduction would lead to depressed LDA. However,
these results show that abLIM-1 is not simply required for the LDA mechanism to
proceed but modulates the response of the cell to stretch by acting as a “brake” on
stretch sensing and LDA. This regulatory paradigm is not unprecedented, as there are
other proteins in cardiac EC-coupling that inhibit activity in a phosphorylation-dependent
manner, such as cMyBP-C and phospholamban. In fact, our experiments with
recombinant Z1Z2 and abLIM-1 show that GSK-3β ablates their interaction and relieves
abLIM-1’s inhibition of passive tension and LDA. See Figure 25 for our proposed
mechanism for how z-disc localized GSK-3β interacts with abLIM-1 to mediate passive

tension and LDA. While this mechanism is not fully elucidated, perhaps abLIM-1
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interacts with T-CAP and Z1Z2 in a way that destabilizes the anchoring of Z1Z2 to the
z-disc via T-CAP, and this weakened, or more compliant, anchoring could result in
decreased passive tension when the sarcomere length is increased. Future studies
should investigate the ability of abLIM-1 to interact with Z1Z2 and T-CAP as a complex.
Co-immunoprecipitation experiments should also be performed in which abLIM-1 is
used as bait in left ventricular tissue, and the eluants can be identified via mass
spectrometry. This could provide a better indication if Z1Z2 and abLIM-1 interact in vivo,
and if there are other proteins bound to this complex. Additionally, there are techniques
outside of co-immunoprecipitation to investigate protein-protein interactions, such as
ITC and SPR, which may provide more insight into the interactions between these
proteins.

Figure 25. Z-Disc Localized GSK-3β Modulates Passive Tension and LDA by
Negative Regulation of abLIM-1.

Limitations
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We performed paired, recombinant GSK-3β treatments on CON and KO
myocytes at either short or long sarcomere lengths. As we did not measure calcium
sensitivity at both sarcomere lengths for the same cells, these cannot be considered
LDA experiments. However, as recombinant GSK-3β only had an effect at long
sarcomere lengths, this supports that its mechanism of action is dependent upon the SL
of the cell. An alternative way of performing these experiments would be to treat cells
with recombinant GSK-3β and performing paired curves at short and long sarcomere
lengths. The effect of GSK-3β on LDA could then be compared to non-GSK-3β treated
cells.
In our treatment experiments, the effect of recombinant GSK-3β on calcium
sensitivity (at long sarcomere lengths) was modest. In fact, we did not identify an effect
of GSK-3β treatment within groups, only the p-value for the treatment factor was
significant. The inability of recombinant GSK-3β to have a more robust effect on calcium
sensitivity may be due to the fact that these cells are permeabilized, with the cytosolic
contents washed away, and if GSK-3β’s mechanism of action is by acting as an
upstream messenger, it is likely that some of the downstream components have been
disabled/negatively affected by the experimental preparations. When we performed
GSK-3β treatments in the cMyBP-C KO mice, we utilized a higher concentration of
GSK-3β in an attempt to maximize the effect. We found that GSK-3β is unable to
sensitize at long sarcomere lengths in the cMyBP-C transgenic mice compared to
control animals. GSK-3β’s inability to sensitize in the cMyBP-C knockout mice, a mouse
model that has dampened LDA, is further evidence that GSK-3β’s mechanism of action
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is via LDA. However, from these experiments alone we cannot definitely say that GSK3β’s mechanism of action in vivo occurs in conjunction with cMyBP-C.
Our work has identified abLIM-1 as a modulator of LDA, however it is important
to note that there a several limitations to this work. Firstly, the LDA experiments
performed on GSK-3β KO mice utilized skinned myocytes, while the LDA experiments
identifying abLIM-1 as a negative modulator were performed in EHTs. The cells with
which the EHTS had been seeded, iPSC-CM, do not have the same myofilament
structure as mature cardiomyocytes. Additionally, calcium sensitivity cannot be
measured on the Myolab system, therefore we have utilized an increase in twitch force

as a readout for LDA. While both skinned myocyte and EHT experiments measure LDA,
their difference should be taken into account.
We found that recombinant GSK-3β can enhance calcium sensitivity at long
sarcomere lengths as well as increase passive tension. While we believe this is due to
the phosphorylation of z-disc targets by GSK-3β, we cannot confirm this. The phosphoproteomics data from Chapter 3 indicates several z-disc targets of GSK-3β, however
there is not sufficient coverage of titin to determine if GSK-3β can phosphorylate titin
directly. As there are several phosphorylation sites on titin which affect calcium
sensitivity95, 225, and we did not identify these sites via mass spectrometry, we cannot
rule out the GSK-3β phosphorylates titin directly to increase calcium sensitivity.
However, because titin is so large it is not feasible to expect 100% coverage when
performing mass spectrometry experiments and current approaches make it impossible
to definitively rule out the possibility that GSK-3β phosphorylates titin.

CHAPTER 5
MYOFILAMENT GSK-3β IS DECREASED IN HEART FAILURE
Introduction
A hallmark of heart failure is pathological remodeling which leads to impaired
systolic and/or diastolic function. A contributing factor to this remodeling is aberrant
kinase signaling, one of the most well-described being chronic beta-adrenergic receptor
activation226. The activation of these receptors activates the kinase PKA, which targets
both calcium handling and myofilament proteins, ultimately increasing contractility.
However, over time there is desensitization of the receptors and diminished PKA
signaling, and the heart has a reduced ability to increase contractility and lusitropy when
its needed. This is detrimental to an already failing heart. Therefore, this shift in kinase
signaling over the course of heart failure ultimately contributes to worsened
cardiovascular function227. However, PKA is not the only kinase that becomes
dysregulated in heart failure. Kinome analyses have shown that kinase expression
becomes altered in human heart failure, and different kinase expression profiles exist
based on the type of injury or cardiomyopathy 3, 228, 229. Therefore, one method of
targeting reverse remodeling is to target kinase driven signaling pathways. However, as
a single upstream singling kinase can have a large net of effect on cell homeostasis,
kinase inhibitors can have off-target effects which are cardiotoxic230. Indeed, several
kinase inhibitors designed to target cancer have resulted in depressed cardiovascular
99

function231-233.

In order to avoid large off-target effects, a better strategy may be to
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design inhibitors that are capable of targeting the kinases ability to phosphorylate a
specific detrimental subset of its downstream substrates.
Like PKA, GSK-3β is a prolific signaling kinase, and its activity is altered in heart
failure. It has been shown in both human heart failure and animal models that GSK-3β
becomes inactivated8, 234 as well as activated235 in heart failure. Several different mouse
models of GSK-3β have been used to investigate its role in adverse remodeling, leading
to somewhat confounding results. Knockout of GSK-3β after trans-aortic constriction
(TAC), which causes pressure overload and hypertrophy, had no effect9. However,
overexpression a GSK-3β mutant which lacks kinase activity was beneficial13.
Interestingly, two different studies which utilized constitutively active GSK-3β found it to
be protective post TAC12, 155. Therefore, these studies have shown that both reducing
and overexpressing GSK-3β’s kinase activity can have beneficial effects during
pressure overload, suggesting a complex regulation of GSK-3β.
In a different model, a reduction of GSK-3β was associated with decreased
myofilament function. In a dog model in which animals with heart failure underwent a left
bundle branch ablation which induced cardiac dyssynchrony14, GSK-3β activity was
decreased and correlated with depressed myofilament function. Cardiac
resynchronization therapy (CRT), which paces the ventricles back into synchrony,
rescued both GSK-3β activity and myofilament function.
Therefore, decreases in GSK-3β’s activity can be beneficial in different heart
failure models, yet the loss of GSK-3β activity in the cardiac dyssynchrony study
appears to be detrimental. This begs the question if the changes in GSK-3β that have

been seen in heart failure are compensatory and protective, or detrimental.
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Overexpression and inhibition studies in healthy, non-heart failure models have given
some insight into this. In two separate mouse models, chronic overexpression of GSK3β led to ventricular dysfunction and premature death, while overexpression of
dominant-negative GSK-3β (that is kinase deficient) resulted in induction of
compensated concentric hypertrophy and enhanced systolic function13. As
overexpression of GSK-3β impaired function, and decreasing its activity was beneficial,
these studies support the decrease in GSK-3β activity in heart failure as being
compensatory and protective.
We have shown in Chapter 4 that the genetic removal of GSK-3β is detrimental
to myofilament function. Therefore, while a decrease in cytosolic GSK-3β may be
beneficial in heart failure in terms of minimizing pathological hypertrophy, fibrosis, and
apoptosis, the loss of myofilament GSK-3β would be detrimental. Myofilament localized
GSK-3β has not been studied in the context of heart failure so it is unknown if it also
decreases or if it is regulated by a different mechanism.
The objective of this study was to determine if myofilament GSK-3β is altered in
both human and an animal model of heart failure. We previously identified a role for
GSK-3β in modulating length-dependent activation (Chapter 4), the molecular
mechanism behind the Frank-Starling law of the heart, which has been shown to be
decreased in both human and animal models of heart failure105, 106, 108, 202. We therefore
hypothesized that GSK-3β would be reduced in heart failure, contributing to decreased
LDA, and that this reduction would occur with the onset of mechanical dyssynchrony.
We utilized a large bank of left ventricle tissue from non-failing (NF) patients and those
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with heart failure (HF), and quantified GSK-3β in the myofilament and soluble fractions.
Additionally, to determine if these samples had reduced LDA, force-calcium
experiments were performed on skinned myocytes from a subset of the samples at
short and long sarcomere lengths. To study GSK-3β in an acute model of heart failure
with mechanical dyssynchrony, we performed myocardial infarction (MI) in wild type

mice and quantified myofilament and soluble GSK-3β from the border-zone of the infarct
after injury. We found that myofilament GSK-3β is decreased in both human and an
animal model of heart failure and found that this decrease occurs early in disease.
Interestingly, GSK-3β KO appears to influence wall strain at baseline and exacerbates
dyssynchrony in the GSK-3β KO animals. The work indicates that decreased GSK-3β,
which likely occurs in the early stages of heart failure, is a promising target in patients
with a depressed Frank-Starling mechanism.
Methods
Human Heart Tissue Preparation
Human study protocols were approved by the IRB at the Cleveland Clinic and
Loyola University Chicago. All patients gave informed consent. Animal studies were
approved by the Loyola University Chicago Health Sciences Division. Left ventricle
samples were prepared as myofilament enrichment and whole tissue lysis as described
previously.
Myocardial Infarction
Mice were intubated under anesthesia. While monitoring via electrocardiogram,
the chest wall was opened with a lateral incision to expose the heart. An 8-0
polypropylene suture was placed around the left anterior descending (LAD) coronary

artery and the coronary artery was occluded by tying the suture. Mice randomly
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assigned to sham surgery experienced the same conditions with the exception of the
suture being tied. Mice were monitored post-surgery and euthanized after forty-eight
hours. The left ventricles were dissected into infarct, border-zone, and remote regions
and preserved in liquid nitrogen.
Echocardiography
Mice were anesthetized with 5% isofluorane before being moved to a nose cone
and kept under 2% isofluorane for the duration of the procedure. Trans-thoracic
echocardiography was performed using a Vevo 3100 ultrasound system. A 30 Hz probe
was used to take parasternal B-mode images of the left ventricle. Speckle-tracking was
used to track peak strain and time to peak strain for both longitudinal and radial strain
patterns using Vevo software.
Statistics
Variables are expressed as mean ± standard error. Statistical significance was
calculated in GraphPad Prism (version 9) by t-test, one-way analysis of variance, or
two-way analysis of variance followed by the Tukey or Mann-Whitney post-hoc tests, as
indicated. Normality (by Shapiro Wilk test) and equal variance (by F-test for t-tests or
Brown-Forsythe test for ANOVAs) were tested prior to all parametric tests. Correlations
between categorical variables was performed with linear regression.
Results
Myofilament GSK-3β is Reduced in Human Heart Failure
In order to quantify changes in myofilament GSK-3β, we used LV myocardium
from human NF rejected donor hearts (n=19) and explanted hearts from HF patients

(n=22, demographics in Table 5). NF hearts consisted of hearts that were absent of
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cardiovascular disease but were unable to be used for transplantation. The HF group
consisted of hearts with both dilated cardiomyopathy (DCM) and ischemic
cardiomyopathy (ICM). These 41 samples were collected from two biobanks (Loyola
University Chicago and Cleveland Clinic). We prepared the samples as both
myofilament enrichments and whole tissue lysis in order to differentiate changes in the
myofilament versus soluble pool.

Table 5. Patient Characteristics for Non-Failing and Heart Failure Samples.
Age, gender, ethnicity, ischemia, and left ventricular ejection fraction (LVEF) for
NF and HF LV samples. P-values were calculated as follows: Age (unpaired ttest), Race (Chi-Square), Sex (Chi-Square), Ischemia (Chi-Square), LVEF (nonparametric t-test, Mann-Whitney Test). Superscripts represent categories with
missing values (1 4 missing values, 2 4 missing values, 3 7 missing values, 4 11
missing values). Missing values have been excluded from statistical analysis.
NONFAILING

HEART FAILURE

P-VALUE

19

22

-

58.3 ± 8.6

53.9 ± 2.71

0.21

% WHITE

94.7%

72.2%2

0.063

% FEMALE

42.1%

40.9%

0.94

0%

63.6%

<0.0001

62.1 ± 2.2%3

21.4 ± 2.0%4

<0.0001

N
AGE (YEARS)

% ISCHEMIC
EF (%)

When we quantified total GSK-3β and its phosphorylated forms (pS9 and
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pY216), we found that myofilament GSK-3β was significantly reduced in myocardium
from HF patients compared to NF hearts (p=0.0019), while whole tissue GSK-3β
remained unchanged (Figure 26A-C). GSK-3β phosphorylated at S9 was significantly
decreased in myofilament enrichment (p=0.0038) but not in whole tissue lysis (Figure
26D-E). GSK-3β phosphorylated at Y216 was unchanged in both myofilament and
whole tissue preparations (Figure 26F-G).
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Figure 26. Myofilament GSK-3β is Reduced in Human Heart Failure. (A)
Representative western blot from myofilament enriched and whole tissue
preparations from NF and HF patients. Total GSK-3β from NF and HF patients from
(B) myofilament enriched tissue (n=17; p=0.0019) and (C) whole tissue lysis (n=1519). pS9 GSK-3β normalized to total GSK-3β in (D) myofilament enrichment (n=1617; p=0.0038) and (E) whole tissue lysis (n=18-19). pY216 normalized to total GSK3β in (F) myofilament enriched tissue (n=16-17) and (G) whole tissue lyisis (n=1416). All groups have been normalized to the respective NF group. Statistics were
performed via unpaired t-test.
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Human HF Samples with Reduced Myofilament GSK-3β Also Have Reduced LDA

As GSK-3β KO mice have reduced calcium sensitivity at long sarcomere lengths
we suspected that myocytes from human heart failure patients with reduced
myofilament GSK-3β would also have reduced calcium sensitivity. We selected the
samples with the highest and lowest levels of either myofilament (n=7-12 cells/3 hearts
per group) or whole tissue GSK-3β (n = 5-7 cells/ 3 hearts per group) and measured
force-calcium relationships at long SL (Figure 27A-F). Hearts with high levels of
myofilament GSK-3β had significantly increased calcium sensitivity (p=0.0168 by
unpaired t-test). There were no statistical differences between these groups when
sorted by whole tissue GSK-3β supporting that whole tissue (primarily cytosolic) GSK3β is not responsible for modulating sarcomeric function.
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Figure 27. Human Samples with Higher Myofilament GSK-3β Have Increased
Calcium Sensitivity. (A) Force-calcium curves of human LV myocytes sorted by
myofilament GSK-3β, low (n= 3 samples, 7 cells) and high (n= 4 samples, 12 cells).
(B) EC50 and (C) Fmax for myofilament sorted samples. Statistics were calculated by
Mann-Whitney test. (D) Force-calcium curves of human LV myocytes sorted by whole
tissue GSK-3β, low (n= 3 samples, 7 cells) and high (n=3 sample, 5 cells).
Experiments were performed at a sarcomere length of 2.1 µm.
Lastly, we tested whether HF patients with diminished sarcomere-localized GSK3β had depressed LDA as the GSK-3β KO mouse model would predict. We measured
force-calcium relationships at both short and long SLs in NF and HF LV (n= 3

hearts/group, 3 cells/heart). Both NF and HF groups experienced an increase in Fmax
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with stretch; however, while we observed increased calcium sensitivity in NF myocytes
when increasing SL, this effect was entirely absent in the HF group (Figure 28A-D).
These data suggest z-disc localized GSK-3β is lost in human heart failure, which
correlates with a loss of LDA. It should be pointed out that the HF cells were sensitized
compared to the NF cells at short sarcomere lengths. An increase in calcium sensitivity
has been observed in cells from human heart failure patients, and this may be due to
beta-adrenergic receptor desensitization and a decrease in PKA activity, as the
targeting of TnI by PKA results in decreased calcium sensitivity.

Figure 28. Human Heart Failure Samples with Reduced GSK-3β Also Have
Reduced LDA. (A) Mean force as a function of calcium concentration and fitted
curves for skinned myocytes from the LV of NF and (B) HF patients from which
measurements were taken at short (1.9 μm) and long (2.3 μm) SL. (C) Fmax and
(D) EC50 depicted as mean± SEM (n = 9 myocytes from 3 patients). P-values
were calculated from two-way repeated measures ANOVA with pair-wise
comparisons.
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Myofilament GSK-3β is Decreased After Myocardial Infarction
The human heart failure samples used in this study were from end-stage heart
failure patients, therefore there is a large amount of variability in terms of genetic and
environmental factors which could affect the etiology and progression of their disease.
Thus, over interpretation of the correlation between sarcomere GSK-3β and LDA should
be avoided. We therefore wanted to investigate if GSK-3β myofilament levels also
decreased acutely after the insult, before the heart drastically remodels. We chose a
permanent ligation myocardial infarction model because it is severe and results in a
near immediate effect on cardiovascular function, compared to inducing heart failure via
trans-aortic constriction or isoproterenol infusion. We also wanted to use a model which
induces cardiac dyssynchrony as GSK-3β activity was previously found to be decreased
in a dog model of cardiac dyssynchrony14 and we hypothesized that this change in
activity may be due to the mechanical disruption that dyssynchrony causes. Utilizing an
MI model, we induced myocardial infarction via ligation and permanent occlusion of the
left anterior descending coronary artery (LAD) in CON and GSK-3β KO mice (n=10),
with Sham surgeries acting as a control (n=6-8). Baseline M-mode echocardiography
was performed the day before the MI and 48 hours post MI, prior to euthanasia, to
assess the severity of the MI (Table 6).
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Table 6. Echocardiography Statistics for Sham and MI Mice. Metrics of left
ventricular function: ejection fraction (EF), fractional shortening (FS) in Sham animals
and those that underwent MI surgeries pre and 48 hours post-surgery. Data is listed
as mean ± SEM. Pre and post values were compared by paired t-test and significant
difference (p<0.05) are noted with*. Sham and MI values were compared for both pre
and post time-points by unpaired t-test and significant difference (p<0.05) are noted
with ^.

Control
Sham (n=8)
Pre

MI (n=10)
Post

Pre

Post

EF (%) 53.64 ± 3.81

56.52 ± 3.21

46.47 ± 2.17

13.11 ± 1.59*^

FS (%) 25.57 ± 2.61

29.26 ± 2.25

23.01 ± 1.34

5.76 ± 0.73*^

GSK-3β KO
Sham (n=6)
Pre

MI (n=10)
Post

Pre

Post

EF (%) 53.96 ± 4.58

62.86 ± 2.19

55.33 ± 2.99

26.81 ± 5.15*^

FS (%) 27.784 ± 2.99

33.29 ± 1.72

25.96 ± 2.35

12.69 ± 2.68*^

The echocardiography analysis revealed that MI induced a decrease in ejection
fraction and fractional shortening, measurements of systolic function, in both CON and
GSK-3β KO mice (n=10), when compared to the paired baseline measurements. Sham
animals did not have a decrease in EF or FS in either group (n values: CON = 8, KO =
6). There were no significant differences in the effect of MI between CON and KO mice,
however there was a trend (p=0.0757; by two way repeated measures ANOVA) for the
KO mice to not have as severe of a decrease in EF post MI compared to CON animals
(Figure 29). It should be noted that of the mice which received MI surgeries, the
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average baseline EF for KO mice was slightly (but not significantly) higher compared to
the CON, and this may be contributing to the trending differences in EF post MI.

Figure 29. Myocardial Infarction Induces a Decrease in Systolic Function.
Ejection Fraction (EF) measurements for CON (Sham n = 8, MI n = 11) and KO
(Sham n = 6, MI n=10) at baseline and 48 hours post MI. Statistics were
performed by Two-way ANOVA with repeated measures.
Aside from gross changes in systolic function, we were interested in if 1) at 48
hours post MI we could quantify the onset of dyssynchrony and 2) if the baseline
decrease in GSK-3β in the GSK-3β KO mice predisposed them to dyssynchrony. We
utilized B-mode longitudinal echocardiography and speckle-tracking based strain
analysis to track wall movement at baseline and 48 hours post MI. MI is expected to
induce an opposing wall delay in contraction, because infarcted tissue contracts weakly
compared to the surrounding tissue. Indeed, MI induced a longitudinal opposing wall
(anterior vs posterior) delay. Indeed, both CON and GSK-3β KO mice (n=10) have a
significantly increased maximal opposing wall delay (ms) (CON p=0.0354; KO
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p=0.0183) (Figure 30A). Interestingly, MI did not induce an increased wall delay in the

radial direction in CON mice but does induce a significant radial wall delay in the GSK3β KO mice (p=0.0024) (Figure 30B). This delay may stem from a trending decrease in
the baseline opposing wall delay in KO mice compared to CON mice (p=0.0865).

Figure 30. Myocardial Infarction (MI) Induces Mechanical Dyssynchrony.
Maximal opposing wall delay (ms) of the left ventricle calculated from strain-analysis
of B-mode echocardiography in the (A) Longitudinal and (B) Radial planes in CON
and GSK-3β KO mice (n=10). P-values were calculated by repeated-measures twoway ANOVA.

Previous work suggested dyssynchrony may effect GSK-3β expression or
activity14, and since the strain analysis indicated that a wall delay was induced by the
MI, we also hypothesized that the MI could induce changes in GSK-3β localization. This
was further supported by the altered GSK-3β localization we observed in chronic endstage human heart failure. We prepared the left ventricular tissue that bordered the
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infarcted region (the border zone) as both myofilament enrichment (n=8-10/group) and
soluble fractions (n=5-6/group) (Figure 31). For sham animals (which did not have an

infarcted region), we utilized the midwall of the left ventricle. We found that myofilament
GSK-3β significantly decreased by ~25% post MI in CON animals (p=0.0193). Soluble
GSK-3β did not significantly decrease post MI (p=0.1531), however it should be noted
that this quantification was not powered to the same number of animals as the
myofilament enrichment.
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Figure 31. Myofilament GSK-3β Decreases in the Border-Zone After Myocardial
Infarction. (A) Representative western blots depicting myofilament and soluble GSK3β in CON and GSK-3β KO Sham and MI mice. Total protein stain has been used as a
loading control (B) Quantification of myofilament GSK-3β normalized to total protein (n
values: CON Sham =9; CON MI = 10; KO Sham = 8; KO MI = 9). (C) Quantification of
soluble GSK-3β normalized to total protein (n values: CON Sham =6; CON MI = 6; KO
Sham = 6; KO MI = 5). P-values were calculated by two-way ANOVA.

Discussion
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In Chapter 4 we showed that GSK-3β is a modulator of LDA, as skinned
myocytes from GSK-3β KO mice did not sensitize to calcium with stretch. As a loss of
LDA or the Frank-Starling mechanism have also been described in human heart failure
and animal models of heart failure105, 106, 202, 236, we hypothesized that myofilament GSK3β decreased in heart failure, at least potentially contributing to dampened LDA. We
found that myofilament GSK-3β, but not whole tissue lysis GSK-3β decreased in the left
ventricle of human heart failure patients, and that a subset of these patients also had
decreased LDA. Using a mouse model of MI, we found that myofilament GSK-3β
decreases just 48 hours after injury with the onset of dyssynchrony.
Myofilament GSK-3β is Reduced in Human HF
GSK-3β activity has been found to be altered in both animal models of heart
disease and human heart failure14, 158, 179, 234. In myocardium from human heart failure
patients, GSK-3β activity has been found to be both increased235 and decreased234, but
prior to our study, myofilament GSK-3β has never been assessed. We found that GSK3β was reduced specifically in myofilament-enriched samples in human heart failure and
not in whole tissue lysis. In the myofilament fraction, GSK-3β phosphorylated at S9 was
reduced in HF. As a decrease in pS9 is typically interpreted as an increase in GSK-3β
activity, this may be a compensatory mechanism to increase GSK-3β activity when total
GSK-3β levels are reduced. Interestingly, we only found a trending decrease (p=0.1121)
in pS9 in the whole tissue lysis preparations, which differs from what has been shown in
the literature (that activity can either increase or decrease). This could be due to
differences in tissue procurement and preparation. In addition, we combined ischemic
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and dilated cardiomyopathy patients into one heart failure group, and it is possible that
soluble GSK-3β activity differs between these groups and combining them loses these
differences.
We found that skinned myocytes from patients with heart failure had reduced
LDA compared to the skinned myocytes from non-failing patients. The decrease in

GSK-3β in our GSK-3β KO mice is sufficient to reduce LDA, but we cannot eliminate the
possibility that other pathways are contributing to its loss in the more complex situation
of human heart failure. However, this loss of GSK-3β may be contributing to or
exacerbating decreased LDA and could be a therapeutic target in improving this
mechanism in heart failure patients.
Loss of LDA in Cardiovascular Disease
It has been shown through computational modeling that loss of LDA is a
contributing factor to Takotsubo, or stress, cardiomyopathy237. In Takotsubo, a flood of
beta-adrenergic stimulation results in an extreme ventricle shape that is termed apical
ballooning- characterized by a hypercontractile base and hypo-contractile apex238.
While it was initially believed that this left ventricular phenotype stemmed from a
differential regional response of the myocardium to catecholamines, modeling has
shown that a loss of the Frank-Starling mechanism contributes to apical ballooning.
While the majority of patients diagnosed with Takotsubo recover, there is no defined
treatment and the mortality rate is 1-3%. It is unknown if GSK-3β decreases in
Takotsubo, but as we have shown that myofilament GSK-3β is important for LDA,
directing GSK-3β towards the myofilament in Takotsubo patients may be a potential
therapeutic for alleviating apical ballooning and improving systolic function. Aside from
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contributing to Takotsubo, this study raises the question if patients with reduced GSK-

3β and LDA are more susceptible for developing Takotsubo when exposed to stressors.
It has been shown that GSK-3β becomes inactivated in a dog model of heart
failure with cardiac dyssynchrony14. In this model, heart failure is induced by
tachypacing and dyssynchrony is induced by left-bundle branch ablation. A subset of
these animals were then treated with cardiac resynchronization therapy (CRT), a
biventricular pacing device, to restore synchrony. Cardiac dyssynchrony resulted in
inactivation of GSK-3β, while CRT reactivated GSK-3β, and it was concluded that the
reactivation of GSK-3β with CRT contributes to improved myofilament, and thus,
cardiovascular function. Despite being an effective therapy, CRT has a relatively high
non-responder rate239. Thus, many groups are working to identify the mechanism by
which CRT acts to improve contractility, so that patients predicted to be non-responders
are not subjected to a therapy they will not benefit from. It is important to note that in the
dog model of cardiac dyssynchrony, all dogs receiving CRT responded with improved
function (100% responder rate) and increased GSK-3β activity, which supports the
connection between GSK-3β and improved myofilament function. Another
computational modeling study found that hearts which lack LDA are more likely to
respond to CRT240. They found that restoration of LDA is required for the
homogenization of tension development in synchronous contraction. As we have shown
that GSK-3β is important for LDA, and it is known that CRT re-activates GSK-3β, this
suggests that the restoration of GSK-3β activity by CRT (and its effect on LDA) makes
up a major beneficial component of CRT. Targeting GSK-3β’s LDA mechanism could

mirror much of the benefit of CRT, specifically in patients suffering from ischemia
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induced dyssynchrony which cannot be treated with a CRT device.
Myofilament GSK-3β is Reduced with Mechanical Dyssynchrony
Several lines of evidence point towards GSK-3β as being regulated by both
mechanical changes and heart failure14, 241. We found that myofilament GSK-3β is
reduced in human heart failure patients with diminished LDA. In our animal study, we
also found that myofilament GSK-3β is reduced by about 30% after MI at a time point
shortly after injury (48 hours). An earlier study, which focused on the role of GSK-3β in
the inflammasome post MI, has shown that GSK-3β increases in the infarcted region 48
hours post MI242, but remains unchanged in the border zone of the infarct (the region we
quantified in our study) until 28 days post myocardial infarction. We did not quantify
GSK-3β in the infarcted region, because we anticipated that this region was infiltrated
with fibroblasts and contained few cardiomyocytes, which were the target of our study
into the sarcomere. However, like this previous work, we quantified GSK-3β in the
border zone, but as both myofilament enrichment and soluble fractions. While we
detected changes in myofilament GSK-3β at 48 hours, like this previous work, we did
not detect changes in soluble GSK-3β. It is likely that the reduction, or re-localization, of
myofilament GSK-3β occurs due to the onset of dyssynchrony, while the decrease in
soluble GSK-3β seen at the 28-day time point is due to the induction of signaling
pathways as the heart remodels. We found that GSK-3β’s myofilament localization is
dependent upon phosphorylation at Y216, and changes in phosphorylation could occur
rapidly as part of a mechano-sensing mechanism.
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It has been well described that an MI will cause cardiac dyssynchrony, because
the infarcted region of the myocardium cannot contract due to the loss of
cardiomyocytes and Perkinje fiber connections243, 244. Mice in the MI group (both CON
and GSK-3β KO) developed a significant opposing wall delay in the longitudinal plane

after MI. The strain software calculates the maximal opposing wall delay as the maximal
amount of time (in ms) between contraction of anterior and posterior walls. This wall
delay post MI likely stems from a delayed contraction of the anterior wall containing the
infarct, and contributes to the decrease in ejection fraction that we saw in both CON and
KO mice. While there were no differences in the ejection fraction post MI between CON
and KO mice, we found that GSK-3β KO mice also developed a significant opposing
wall delay in the radial plane. Perhaps the loss of GSK-3β in the KO mice disrupts
synchrony at baseline, and then further exacerbates it post MI. However, this cannot be
concluded from our measurements of systolic function. Perhaps at longer time point,
chronic dyssynchrony would further depress the ejection fraction would reveal these
differences between CON and GSK-3β KO mice.
Limitations
We utilized an acute, 48-hour time point in our MI studies because we wanted to
assess myofilament GSK-3β at the early stages of dyssynchrony, prior to gross
ventricular remodeling. At 48 hours we found that myofilament GSK-3β significantly
decreased, which occurred with the onset of dyssynchrony. This led us to hypothesize
that the dyssynchrony could be inducing the altered GSK-3β localization. However
further studies are required to determine a true causation between dyssynchrony and a

decrease in myofilament GSK-3β. This could be accomplished by quantifying
myofilament GSK-3β in a model of dyssynchrony absent of heart failure.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS
Summary of Dissertation Work
GSK-3β Localizes to the Z-Disc via pY216 and Phosphorylates Z-Disc Proteins
In cardiomyocytes, the serine/threonine GSK-3β localizes to the cytosol126,
nucleus245, and mitochondria158, 246. Typically, when GSK-3β protein expression and
activity are quantified these subcellular fractions are not taken into consideration.
Subcellular compartmentalization of a kinase can allow it to act as an entirely separate
kinase, with unique substrates and regulation. Therefore, some of GSK-3β’s functions
may be undescribed in previous work if subcellular fractions have been homogenized.
Arguably, GSK-3β’s role at the myofilament has been the least explored. Others
have provided evidence that GSK-3β can phosphorylate myofilament targets in vitro 14
and that it is likely altered in disease14, 161, 179. These studies suggest that GSK-3β can
localize to the myofilament and plays a role in modulating function, however it is unclear
from this work if GSK-3β modulates myofilament function in vivo.
In Chapter 3, we characterized myofilament localized GSK-3β, explored a
mechanism by which it localizes, and identified GSK-3β’s myofilament specific phosphotargets. We identified GSK-3β in both myofilament and soluble fractions of left ventricle
tissue from wild type mice. We used permeabilized myocytes from non-failing donor
hearts and probed with antibodies for total GSK-3β and its two well described
122
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phosphorylation sites, pS9 and pY216. Interestingly, total GSK-3β and pY216 GSK-3β
co-localized with the z-disc protein ⍺-actinin, with the pY216 antibody having the

strongest co-localization. Phosphorylation at Y216 is associated with increased kinase

activity149, however it has not been connected to changes in the localization of GSK-3β
in cardiomyocytes. To further explore the role of pY216 in GSK-3β’s myofilament
localization we performed several experiments. First, we did co-immunoprecipitation
experiments with myofilament enriched tissue, pulling down with total GSK-3β, pS9, and
pY216 antibodies. The pY216 antibodies pulled down significantly more myofilament
proteins than the total GSK-3β or pS9 antibodies. We therefore sought to determine if
phosphorylation at Y216 could drive GSK-3β towards or away from the myofilament by
overexpressing adenoviruses for wildtype, Y216F (blocked phosphorylation), and
Y216E (phospho-mimetic) in neonatal rat ventricular cardiomyocytes (NRVMs). Cell
lysates were then used for co-immunoprecipitation experiments in which we pulled
down with the myc-tag conjugated to each adenoviral construct. Cells expressing
Y216E pulled down significantly more myofilament proteins than the wild type and
Y216F. While it is unclear from these experiments if the Y216 residue is the only factor
driving localization, this work provides evidence for phosphorylation of this residue
being a large influence on GSK-3β’s myofilament localization.
As previous work provided evidence that GSK-3β can phosphorylate myofilament
substrates in vitro14, we were interested in determining if GSK-3β can phosphorylate
myofilament substrates in vivo. We therefore used myofilament enriched tissue from a
cardiomyocyte specific GSK-3β KO mouse for phospho-proteomic experiments. From
this work we identified several phosphorylations on myofilament proteins that were

decreased in the GSK-3β KO mice, implying that GSK-3β targets these residues.
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Notably, none of these sites have been previously shown to be associated with changes
to myofilament function, however several of the proteins (SPEG, Supervillin, and abLIM1) localize to the z-disc (where we also found GSK-3β to localize).
GSK-3β Modulates Length-Dependent Activation via Titin-Based Strain
GSK-3β is a negative regulator of cardiomyocyte hypertrophy, making it an
important modulator of cardiovascular function. It has also been shown that GSK-3β can
also affect myofilament function, specifically, that GSK-3β can increase myofilament
calcium sensitivity 14. However, this work was performed in vitro, and it was unclear if
GSK-3β can increase calcium sensitivity in vivo as well. Therefore, in Chapter 4 we
explored the role of GSK-3β in myofilament function using cardiomyocyte-specific,
inducible GSK-3β KO mice. GSK-3β was found to be altered in a model of cardiac
dyssynchrony, which induces mechanical dysfunction14. To determine if GSK-3β is
important for mechano-transduction, we performed length-dependent activation (LDA)
experiments on cells isolated from the left ventricle of CON and GSK-3β KO mice. LDA
is the mechanism by which stretch (or an increase in sarcomere length) results in
sensitization of the myofilament to calcium. We found that LDA was dampened in cells
from the the GSK-3β KO mice compared to littermate controls, meaning they do not
sensitize to calcium with stretch. Additionally, we found that recombinant GSK-3β can
sensitize at long, but not short, sarcomere lengths, implying that length is a factor in
GSK-3β’s ability to sensitize. To further explore the role of GSK-3β’s in calcium
sensitivity in the context of LDA, we sought to determine if recombinant GSK-3β could
sensitize in a mouse model which already lacks LDA, a cardiac myosin binding protein-

C (cMyBP-C) KO

mouse216.
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Indeed, GSK-3β treatment could not sensitize in the model,

further providing evidence that GSK-3β’s mechanism of action is via LDA and upstream
of cMyBP-C.
LDA or the Frank-Starling mechanism have been found to be depressed in
human heart failure and animal models of heart failure105, 106, 201, 202, 240. Due to this
clinical relevancy, we wanted to determine why GSK-3β KO mice had decreased LDA.
We explored factors that can modulate LDA, such as the phosphorylation of TnI and
cMyBP-C82, lattice spacing111, 115, 116, and passive tension98, 118. While there were no
changes in TnI and cMyBP-C phosphorylation and lattice spacing, passive tension, a
property of titin, was reduced in the KO mice, and this could be rescued with
recombinant GSK-3β treatment. These changes to passive tension were not due to titin
isoform switching. As changes to titin compliance have been linked to LDA, we believe
that GSK-3β modulation of LDA occurs upstream of titin.
We hypothesized that GSK-3β’s myofilament localization and phosphorylation of
z-disc targets leads to changes in the ability of titin to anchor to the z-disc. We therefore
chose to determine if one of its substrates, identified in Chapter 3, was important for
LDA. We chose to explore actin binding LIM domain protein 1 (abLIM-1), because other
LIM domain proteins are established stress/strain sensors and abLIM-1 was identified
as an in vitro target of GSK-3β in a previous study14, 247. Interestingly, we found that
abLIM-1 can interact with the Z1Z2 domains of titin, which anchor titin to the z-disc. In
addition, we found that abLIM-1 is a negative regulator of LDA and believe that
phosphorylation by GSK-3β may further modulate this regulation.

GSK-3β is Decreased in Heart Failure

126

In Chapter 4 we determined that GSK-3β is important for LDA. As LDA can
become depressed in heart failure, we wanted to determine if myofilament GSK-3β is
also decreased in heart failure. Therefore, in Chapter 5 we explored myofilament GSK3β in both human heart tissue and an animal model of heart failure. We utilized a large
tissue bank of human non-failing (NF) and heart failure (HF) bank and enriched this left
ventricular tissue for the myofilament. We also utilized the tissue for a whole tissue lysis,
to compare any changes at the myofilament to changes in the soluble fraction. Samples
from HF patients had significantly decreased myofilament GSK-3β, yet no changes in
whole tissue GSK-3β. We interpreted this as GSK-3β localizing away from the
myofilament in heart failure. Importantly, we performed LDA experiments on skinned
myocytes from a subset of the NF and HF patients and found that LDA was reduced in
the HF patients. While the decrease in myofilament GSK-3β and decrease in LDA in the
HF patients is purely correlative, we believe this should be explored in future work.
Because these were transplanted hearts from end-stage heart failure patients,
we wanted to determine at what point in the progression of disease myofilament GSK3β decreased. We chose to use a myocardial infarction (MI) model, because this is an
acute injury, but also because it can induce cardiac dyssynchrony. Dyssynchrony was
previously attributed to changes in GSK-3β activity14, and we were interested in if any
decreases in myofilament GSK-3β would occur with the onset of dyssynchrony. At 48
hours post MI, mice from our model developed dyssynchrony, determined via
echocardiography and a strain analysis. Also, at this time point myofilament GSK-3β
significantly decreased compared to the control Sham animals. We concluded from this

experiment that the decrease in myofilament GSK-3β seen in human heart failure (at
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least heart failure secondary to an MI) likely occurs early in the disease progression.
These experiments highlight GSK-3β as a promising therapeutic target for patients with
heart failure and reduced LDA.
Future Directions
Utilizing GSK-3β Phospho-Mutants to Direct GSK-3β to the Myofilament
In Chapter 3 we investigated the importance of Y216 in directing GSK-3β
towards the myofilament, with the phospho-mimetic Y216E having more myofilament
affiliation than the phospho-null Y216F. In Chapter 4 we determined that GSK-3β is
important for myofilament function, specifically, for passive tension and LDA. Therefore,
we would hypothesize that cells expressing Y216F would have less myofilament GSK3β and reduced LDA, while cells expressing Y216E would have more myofilament GSK3β and increase LDA. Our experiments were performed in NRVMs, which are ideal for
overexpression studies because they can be kept in culture longer than adult
cardiomyocytes. However, due to the immature shape of NRVMs, they are not able to
be used for the type of LDA and passive tension experiments performed on adult
cardiomyocytes from the GSK-3β KO mice in Chapter 4.
To explore the connection between Y216 phosphorylation, GSK-3β myofilament
localization, and LDA in vivo, we have generated a constitutive, global, Y216F mouse.
We attempted to also make a Y216E mouse, but the mutation was not efficiently
introduced. We were able to identify two different animals which contained the correct
Y216F mutation and have generated two separate lines from these animals. Offspring
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from these animals were rederived and backcrossed several times in order to eliminate
non-specific mutations that occurred due to CRISPR.
Interestingly, we are unable to generate animals that are homozygous dominant

for Y216F, leading us to hypothesize this homozygous mutation is embryonic lethal. For
this reason all of the following experiments utilized mice that are heterozygous for
Y216F. Heterozygotes have reduced (by ~25%) soluble GSK-3β (p=0.0002) as well as
pS9 (p=0.0957) and pY216 (p=0.0077) (Figure 21A-D). Myofilament GSK-3β is also
reduced, but this decrease is not significant (p=0.0920), and both phospho-sites do not
differ between groups in myofilament enrichments (Figure 32E-G). We hypothesized
that the decrease in GSK-3β was due to it being degraded after translation. To test this,
we used qPCR to measure GSK-3β transcript levels and have found that these are
unchanged from the control animals (Figure 32H), supporting this hypothesis. However,
if this were the case, we would expect a 50% reduction of total GSK-3β protein in the
heterozygous mice, but we only observed a 25% reduction. One possibility to explain
this difference is that the wild type copy of GSK-3β may be upregulated in an attempt to
compensate, although we would expect to also see an increase in the mRNA transcript,
which we do not. It is possible that some, but not all, of the Y216F GSK-3β is being
actively translated. The possibility of a portion, or all, of the Y216F being degraded is
supported by a study which found that the Y216 residue is auto-phosphorylated during
protein folding149. As deletion of GSK-3β is embryonic lethal6 this would also explain
why we cannot produce homozygous dominant animals.
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Figure 32. Phospho-Null Y216F Results in Reduced Total GSK-3β Protein.
(A) Representative western blots of left ventricular tissue prepped from CON and
animals heterozygous for Y216F mice. Tissue has been prepped as soluble and
myofilament enrichment fractions. Blots depict total GSK-3β, pS9 GSK-3β, pY216
GSK-3β, and total protein stain. Quantification of soluble (n=5-6) (B) total GSK-3β
(p=0.0002) (C) pS9 GSK-3β (D) pY216 GSK-3β (p=0.0077) and myofilament (n=6) (E)
total GSK-3β (F) pS9 GSK-3β (G) pY216 GSK-3β. (H) Adjusted fold change of GSK-3β
mRNA (n=6). Statistics were performed by unpaired t-test.
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We were able to successfully express Y216F and Y216E in NRVMs in Chapter 3,
which we confirmed with western blot by blotting for their tags. In these studies, we
overexpressed the phospho-mutants in the presence of endogenous GSK-3β, while in
the Y216F mice, the mutant GSK-3β is not being overexpressed and should be
replacing the wild type, endogenous GSK-3β. Perhaps in the NRVM studies, Y216F and
Y216E GSK-3β are not degraded because the endogenous GSK-3β is performing a
required function, but in the Y216F mice, Y216F GSK-3β is not able to perform this task
and is therefore degraded. Another difference from the NRVM studies is that we
overexpressed Y216F and Y216E for 72 hours. The Y216F mutation is constitutive in
the mouse model, and we aged the mice to 12 weeks prior to quantifying GSK-3β in the
hearts. It is possible that Y216F GSK-3β becomes downregulated over time. This could
be explored by quantifying GSK-3β in animals from earlier time points. As this is a
global mutation, it would also be beneficial to quantify GSK-3β in other tissue types to
determine if this reduction is caused by a specific mechanism in the heart or if this
reduction occurs in the Y216F mice in other tissue types.
Regional Differences in Myofilament GSK-3β Modulate Function
Strain analyses are oftentimes used to detect differences in wall movement that
occur prior to large changes in global left ventricular function. We did not detect
differences in general indices of systolic function in the GSK-3β KO mice via traditional
m-mode echocardiography (Chapter 4), but we did find the GSK-3β KO mice had
reduced LDA (Chapter 5). We were curious if this reduced myofilament function would
lead to changes in global heart function that could not be identified by 2D
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echocardiography. Given that we were recently given the opportunity to beta-test new

4D strain software, we performed 4D echocardiography and strain analysis on GSK-3β
CON and KO mice (n = 14-17)248, 249. This analysis provides measurements for peak
strain as well as systolic and diastolic rates for circumferential, longitudinal, surface
area, and transmural strain. While we did not identify differences in peak strain between
CON and KO mice, we did find some interesting regional differences in the surface area
systolic strain rate in CON mice that were absent in the GSK-3β KO mice. Specifically,
we found that in the midwall of the left ventricle, the systolic strain rate of the posterior
wall is significantly decreased (n=14; p=0.0005 by repeated measures two-way
ANOVA) compared to the anterior wall in CON animals, (Figure 33). This difference is
absent in GSK-3β KO mice (n=17; p=0.3883 by repeated measures two-way ANOVA).

Figure 33. Regional Differences in Strain are Ablated by GSK-3β KO. Systolic
peak strain and strain rate of the anterior and posterior midwall determined from
surface area strain. Statistics were calculated by two-way repeated measures
ANOVA. (n=14-17 mice/group)

We were thus interested in why the regional differences in systolic strain rate
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were ablated by GSK-3β knockout. We hypothesized that there are baseline differences
in GSK-3β in the anterior and posterior walls, and that these differences are reduced
when knockout ablates GSK-3β. We dissected CON and GSK-3β KO mouse left
ventricles into anterior and posterior sections and prepped them as both myofilament
enrichments and soluble fractions and probed for total GSK-3β and its phosphorylated
forms (pS9 and pY216) (Figure 34A). In CON animals, we found that myofilament
GSK-3β decreases (p=0.0016) while soluble GSK-3β increases (p=0.0157) in the
posterior wall compared to the anterior wall (Figure 34B-C). In both myofilament and
soluble fraction, pS9 GSK-3β decreases in the posterior wall (p=0.0183 and p=0.0005,
respectively) (Figure 34D-E). There were no changes in pY216 GSK-3β in the
myofilament fraction, but pY216 GSK-3β was decreased (p=0.0367) in the posterior wall
in the soluble fraction (Figure 34F-G). There were no differences in total GSK-3β, pS9
GSK-3β, and pY216 GSK-3β between anterior and posterior wall in the GSK-3β KO
mice in either myofilament or soluble fraction.
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Figure 34. There Are Regional Differences in GSK-3β Across the Left Ventricle.
(A) Representative western blots depicting GSK-3β and total protein from myofilament
enrichments and soluble fractions from anterior (ANT) and posterior (POS) walls of the
left ventricle. Quantification of Total GSK-3β for (B) myofilament enrichments and (C)
soluble fractions pS9 GSK-3β from (D) myofilament and (E) soluble fractions and pY216
GSK-3β from (F) myofilament and (G) soluble fractions from the anterior and posterior
walls from CON and GSK-3β KO mice. n values: CON= 14, KO=12. P-values determined
by two-way ANOVA with repeated measures.

As we have shown that GSK-3β is important for myofilament function, we
hypothesize that these small regional differences in GSK-3β (both myofilament and
soluble) are contributing to regional strain differences, and that these regional strain
differences are important for global synchronous contractions. A beneficial future
experiment would be to incorporate our protein expression and functional data into a
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modeling program, as others have done, to try to determine if this would predict regional
differences in strain. Additional work should also focus on exploring the mechanism by
which regional differences in GSK-3β influence strain. From a myofilament perspective
we have shown that GSK-3β is important for length-dependent activation. Others have
shown that GSK-3β is also capable of regulating Ktr161. Soluble GSK-3β regulates
SERCA expression160, which may impact wall strain during diastole.
Concluding Remarks
Our work has focused on identifying a myofilament specific role for GSK-3β, a
kinase that is already established as a critical regulator of cardiovascular function. We

have shown and provided a mechanism for how GSK-3β can localize to the myofilament
and impact myofilament function. Specifically, we have shown that GSK-3β can
influence the Frank-Starling law of the heart through modulation of length-dependent
activation. The Frank-Starling mechanism can become lost in heart failure, exacerbating
already depressed cardiovascular function. Currently there are no therapeutics that
directly target length-dependent activation. While we have provided evidence for the
mechanism of action by which GSK-3β influences LDA, future work should focus on
elucidating this mechanism, specifically how GSK-3β myofilament substrates
individually contribute to contractile function. We have identified abLIM-1 as a modulator
of LDA, however we have yet to explore if GSK-3β’s phosphorylation of abLIM-1 further
alters LDA. Our on-going work has explored mechanisms of targeting GSK-3β to the
myofilament in vivo- experiments which will be critical for attempting to utilize GSK-3β
as a therapeutic in models of heart failure with diminished GSK-3β. In addition to
utilization of myofilament GSK-3β as a treatment, our work in human heart failure
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patients indicates that myofilament GSK-3β may be a potential biomarker for depressed
LDA and the ability of the heart to respond to therapies.

APPENDIX A
SECONDARY ANTIBODY AND IG CONTROLS FOR IMMUNOFLUORESCENCE
EXPERIMENTS
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Appendix A. Figure A. Antibody Controls in Human LV. Human LV
stained with primary antibodies (A) total GSK-3β and (B) and actinin, with (C)
corresponding brightfield image. IgG controls of (D) rabbit IgG and (E) mouse
IgG and (F) corresponding brightfield image. Secondary controls of (G)
alexa-fluor 488 anti-rabbit and (H) alexa-fluor 568 anti-mouse with (I)
corresponding brightfield image. Scale bars = 10 microns.
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Appendix A. Figure B. Antibody Controls in Mouse LV. Mouse LV stained with primary
antibodies (A) total GSK-3β and (B) and actinin, with (C) corresponding brightfield image.
IgG controls of (D) rabbit IgG and (E) mouse IgG and (F) corresponding brightfield image.
Secondary controls of (G) alexa-fluor 488 anti-rabbit and (H) alexa-fluor 568 anti-mouse
with (I) corresponding brightfield image. Scale bars = 10 microns.
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